US Pat. No. 10,215,073

CATALYZED SOOT FILTER FOR USE IN PASSIVE SELECTIVE CATALYTIC REDUCTION

BASF Corporation, Florha...

1. A catalyzed soot filter comprising a porous wall flow substrate, a catalyst for selective catalytic reduction (SCR), a palladium component, and a platinum component,the wall flow substrate comprising an inlet end, an outlet end, a substrate axial length extending between the inlet end and the outlet end, and a plurality of channels defined by internal walls of the wall flow substrate, wherein the plurality of channels comprise inlet channels having an open inlet end and a closed outlet end, and outlet channels having a closed inlet end and an open outlet end,
wherein the SCR catalyst is on the entire surface of the inlet channel walls and on at least a portion of the surface of the pores within the channel walls underneath the surface of the channel walls coated with the SCR catalyst,
wherein the palladium component is on a portion of the surface of the inlet channel walls and on at least a portion of the surface of the pores within the channel walls underneath the surface of the portions of the channel walls coated with the palladium component,
wherein the portion of the inlet channel walls coated with the palladium component extends from the inlet end to x % of the substrate axial length with 0 wherein the platinum component is on a portion of the surface of the outlet channel walls and on at least a portion of the surface of the pores within the channel walls within the surface of the portions of the channel walls coated with the platinum component, wherein the portion of the outlet channel walls coated with the platinum component extends from the outlet end to 100-x % of the substrate axial length.
US Pat. No. 10,214,562

PEPTIDES AND METHODS OF USING SAME

Serpin Pharma, LLC, Noke...

1. A method of improving glycemic control in a subject having hyperglycemia comprising:administering to the subject having hyperglycemia an oral formulation comprising a peptide selected from the group consisting of:
(a) a peptide comprising the amino acid sequence X1-Z1-F-N-K-P-F-X2-Z2-X3-Z3 (SEQ ID NO: 2), wherein
X1 is V or L;
X2 is V, L or M;
X3 is M, I or V;
Z1 is any amino acid;
Z2 is a sequence of any two amino acids; and
Z3 is a sequence of any five amino acids, and wherein the peptide is 21 or fewer amino acids long; and
(b) a peptide comprising the amino acid sequence VKFNKPFVFLMIEQNTK (SEQ ID NO: 1) and wherein the peptide is 21 or fewer amino acids long.
US Pat. No. 10,214,818

ANTI-CORROSIVE ZINC PRIMER COATING COMPOSITIONS COMPRISING HOLLOW GLASS SPHERES AND A CONDUCTIVE PIGMENT

1. An anti-corrosive zinc primer coating composition comprising:a) an alkali metal silicate binder system or an alkyl silicate binder system wherein the alkyl silicate binder system includes one or more alkyl silicate resins selected from the group consisting of ethyl silicates and other alkyl silicates wherein the alkyl groups contain from 1 to 8 carbon atoms,
b) zinc particles,
c) a thickening agent,
d) uncoated hollow glass microspheres, and
e) a conductive pigment selected from the group consisting of graphite, carbon black, aluminium pigments, black iron oxide, antimony-doped tin oxide, mica coated with antimony-doped tin oxide, carbon nanotubes, carbon fibres, and any mixture thereof,
wherein said silicate-based binder system is solvent-based or water-based, and wherein all uncoated hollow glass microspheres have a particle size such that the D50 diameter over the combined pool of all uncoated hollow glass microspheres is in the range of about 20 to 200 ?m.
US Pat. No. 10,216,098

TEST STRUCTURE FOR USE IN METROLOGY MEASUREMENTS OF PATTERNS

NOVA MEASURING INSTRUMENT...

1. A method for creating a test structure for use in metrology measurements of a sample pattern produced by a predetermined multi-patterning scheme, the method comprising: applying a multi-patterning process to a test site for creating a test pattern based on design rules of the sample pattern and configured to enable focusing the metrology measurements on at least one selected feature of the sample pattern, wherein said multi-patterning process applied to the test site either comprises said multi-patterning scheme and at least one additional patterning stage or comprises said multi-patterning scheme while modifying at least one patterning stage of said multi-patterning scheme, such that said multi-patterning process creates in the test site a part of the sample pattern and at least one blocking layer at least partially blocking features of the sample pattern adjacent to said at least one selected feature.
US Pat. No. 10,214,564

ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN

Academia Sinica, Taipei ...

1. A pharmaceutical composition comprising:(a) an effective amount of an isolated peptide, wherein the peptide consists of a protecting group and the amino acid sequence of SEQ ID NO:1, and exhibits an anti-bacterial or anti-fungal activity; and
(b) a pharmaceutically acceptable carrier.
US Pat. No. 10,214,565

COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES

University of Louisville ...

1. A polypeptide comprising a VP2 polypeptide with at least one amino acid modification relative to wild type VP2wherein
the wild type VP2 has the amino acid sequence of SEQ ID NO: 1 and
the at least one amino acid modification comprises a substitution at Y401, a substitution at Q399, a substitution at Q400, a substitution at Q404, a substitution at Q368, a substitution at Q369, a substitution at Y392, Y401F, Y401W, Y401A, Q368A, Q369A, Q368N, Q369N, Q399N, Q400N, Q404T, Y392A, Y392F, Q404N, Y401P, T402A, D403A, Q404A, or combinations thereof.
US Pat. No. 10,214,566

MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF

The Regents of the Univer...

1. An infectious recombinant adeno-associated virus (rAAV) virion comprising:a) a variant AAV capsid protein comprising an amino acid sequence having at least 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:31, and comprising an A593E and/or a D594E substitution relative to AAV2, wherein the substitution results in decreased binding to a neutralizing antibody, compared to the binding of a wild-type AAV virion to the neutralizing antibody; and
b) a heterologous nucleic acid.
US Pat. No. 10,216,871

METHODS AND APPARATUS FOR PREDICTING GLASS DYNAMICS

Corning Incorporated, Co...

16. A method of making a glass article comprising:(I) melting batch materials to produce molten glass; and
(II) forming a glass article from the molten glass;
wherein:
(A) the batch materials comprise a plurality of viscosity-affecting components which become at least part of the glass article; and
(B) the method is characterized by said viscosity-affecting components and/or their concentrations having been selected at least in part using computer-implemented modeling where predicted/estimated non-equilibrium viscosity of the molten glass is a function of time, temperature, and composition.
US Pat. No. 10,214,567

TAGGED HEPADNAVIRUS E ANTIGEN AND ITS USE IN SCREENING ANTIVIRAL SUBSTANCES

Drexel University, Phila...

1. A nucleic acid molecule comprising a nucleic acid sequence encoding a tagged hepadnavirus e antigen, wherein the nucleic acid molecule comprises a sequence encoding one or more tags, wherein the sequence is inserted into an epsilon structure as encoded by a hepadnavirus genome, wherein said nucleic acid molecule comprising a sequence encoding the one or more tag is inserted between nucleotides corresponding to position C1902 and position A1903 of the HBV genome, wherein said nucleic acid molecule comprises 5? of the sequence encoding the one or more tag a sequence that is capable of forming base pairs with the lower stem of the epsilon structure as encoded by a hepadnavirus genome and wherein the sequence that is capable of forming base pairs with said lower stem of the epsilon structure as encoded by a hepadnavirus genome is capable of forming base pairs with nucleotides corresponding to positions T1849 to A1854 of the HBV genome.
US Pat. No. 10,213,544

METHODS FOR TREATING A SUSPENSION OF MONONUCLEAR CELLS TO FACILITATE EXTRACORPOREAL PHOTOPHERESIS

Fenwal, Inc., Lake Zuric...

1. A method for performing extracorporeal photopheresis of mononuclear cells comprising:withdrawing whole blood from a human subject;
introducing said whole blood into a separation chamber of an apheresis device;
separating mononuclear cells from red blood cells and plasma of said whole blood in said separation chamber;
collecting a suspension of mononuclear cells, said suspension further comprising at least residual red blood cells and residual plasma;
withdrawing said red blood cells and plasma that have been separated from said mononuclear cells from said separation chamber;
combining the collected suspension with a lysing solution;
incubating the suspension to lyse the residual red blood cells;
returning said mononuclear cell suspension to said separation chamber of said apheresis device after said withdrawing;
separating within said apheresis device said mononuclear cells from hemoglobin freed by the lysis of residual red blood cells, residual plasma and any lysing solution in said suspension;
removing from the suspension residual plasma, hemoglobin freed by the lysis of the red blood cells and any lysing solution by washing the suspension with saline by centrifugation;
adding an ultraviolet light activated agent to the saline-washed suspension;
irradiating the saline-washed suspension with ultraviolet light;
introducing said irradiated suspension into said separation chamber of said apheresis device;
concentrating the cells so as to have a smaller total volume of said suspension; and
reinfusing the suspension of concentrated cells having the smaller total volume into the human subject without increasing the total volume with additional plasma.
US Pat. No. 10,214,568

METHOD FOR PREPARING PHYCOCYANIN

Ezaki Glico Co., Ltd., O...

1. A preparation method for phycocyanin, comprising: simultaneously adding chitosan and activated carbon to a suspension of cyanobacteria containing phycocyanin to form a flocculent; and filtering the flocculent using a filter,wherein the suspension to be filtered comprises tap water or a buffer, and wherein the concentration of the chitosan in the suspension to be filtered is from 0.01 to 1% by weight and
wherein the weight ratio of chitosan:cyanobacteria is from 0.375:3 to 0.6:3.
US Pat. No. 10,214,569

FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A

GlaxoSmithKline Biologica...

1. A fusion protein of formula I:(X)m—(R1)n-A-(Y)o—B—(Z)p  (formula I)
wherein:
X is a signal peptide or MHHHHHH (SEQ ID NO. 2);
m is 0 or 1;
R1 is an amino acid;
n is 0, 1, 2, 3, 4, 5 or 6;
A is an immunogenic fragment of Protein E from Haemophilus influenzae wherein the immunogenic fragment is selected from SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 179, or SEQ ID NO: 180 or wherein the immunogenic fragment is a sequence having at least 95% sequence identity to any one of SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 179, or SEQ ID NO: 180;
Y is selected from the group consisting of GG, SG, SS, GGG and (G)h wherein h is 4, 5, 6, 7, 8, 9, or 10;
o is 0 or 1;
B is an immunogenic fragment of Pilin A (PilA) from Haemophilus influenzae, wherein the immunogenic fragment of PilA is at least 95% identical to amino acids 40-149 of SEQ ID NO. 58;
Z is GGHHHHHH (SEQ ID NO. 3); and
p is 0 or 1.
US Pat. No. 10,214,570

SPECIFIC ACTIVE SITE INHIBITORS OF ENZYMES AND METHODS OF PRODUCING SAME

THE GOVERNING COUNCIL OF ...

1. A specific inhibitor of a deubiquitinating enzyme, wherein the deubiquitinating enzyme is USP8, and wherein the inhibitor is ubiquitin variant comprising the amino acid sequence set forth in SEQ ID NO: 2 or 3.
US Pat. No. 10,216,107

TONER AND METHOD OF PRODUCING TONER

CANON KABUSHIKI KAISHA, ...

1. A toner comprising a toner particle that contains a binder resin and a wax, whereinthe solubility parameter SP of the binder resin is at least 9.4 and not more than 10.0,
the binder resin contains a resin having a structure represented by the following formula (1) in the terminal position on a main chain of the resin,
*—CO—R  formula (1)
wherein in formula (1), R represents a phenyl group or a derivative thereof, or —COOR1, R1 represents an alkyl group having 1 to 4 carbons, and * represents a bond to the main chain of the resin,
the solubility parameter SW of the wax is at least 8.1 and not more than 9.0, and
SP and SW satisfy formula (2).
|SP?SW|>0.5  formula (2)
US Pat. No. 10,214,572

DUAL-AAV VECTOR-BASED SYSTEMS AND METHODS FOR DELIVERING OVERSIZED GENES TO MAMMALIAN CELLS

University of Florida Res...

1. A polynucleotide vector system comprising i) a first AAV vector polynucleotide comprising an inverted terminal repeat at each end of the polynucleotide, and between the inverted terminal repeats a promoter followed by a partial coding sequence that encodes an N-terminal part of a selected full-length polypeptide, and ii) a second AAV vector polynucleotide comprising an inverted terminal repeat at each end of the polynucleotide, and between the inverted terminal repeats a partial coding sequence that encodes a C-terminal part of the selected full-length polypeptide, and optionally followed by a polyadenylation (pA) signal sequence, wherein the polynucleotide sequence encoding the polypeptide sequence in the first and second AAV vectors comprises polynucleotide sequence that overlaps, wherein the encoded polypeptide is human myosin VIIa, and wherein the first AAV vector polynucleotide comprises the nucleotide sequence of SEQ ID NO:1, and the second AAV vector polynucleotide comprises the nucleotide sequence of SEQ ID NO:2.
US Pat. No. 10,217,645

CHEMICAL MECHANICAL POLISHING (CMP) OF COBALT-CONTAINING SUBSTRATE

VERSUM MATERIALS US, LLC,...

1. A method of a selective chemical mechanical polishing comprising:a) providing a semiconductor substrate having a surface containing a first material and at least one second material;
wherein the first material is Co and the second material is selected from the group consisting of dielectric film, low-k and ultra low-k film, and barrier film;
b) providing a polishing pad;
c) providing a chemical mechanical polishing composition comprising
0.005 wt % to 25 wt % of an abrasive;
0.05 wt % to 10 wt % of at least two chelators;
DI water; and
at least one selected from the group consisting of:
0.0005 wt % to 0.25 wt % of a chemical additive as corrosion inhibitor or a defect reducing agent;
0.005 wt % to 0.5 wt % of a pH adjusting agent;
0.1 wt % to 10 wt % of an oxidizing agent;
0.0001 wt % to 0.10 wt % of biocide; and
0.0005 wt % to 0.15 wt % of a surfactant;
wherein the chemical mechanical polishing (CMP) polishing composition having a pH from 3.5 to 8.5; and
the at least two chelators are amino acids independently selected from the group consisting of DL-Alanine, D-Alanine, L-Alanine, Glycine, Serine, Proline, Histidine, Isoleucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine, Asparagine, Aspartic acid, Glutamine, Ornithine, Selenocystein, Tyrosine, Sarcosine, Bicine, Tricine, Aceglutamide, N-Acetylaspartic acid, Acetylcarnitine, Acetylcysteine, N-Acetylglutamic acid, Acetylleucine, Acivicin, S-Adenosyl-L-homocysteine, Agaritine, Alanosine, Aminohippuric acid, L-Arginine ethyl ester, Aspartame, Aspartylglucosamine, Benzylmercapturic acid, Biocytin, Brivanib alaninate, Carbocisteine, N(6)-Carboxymethyllysine, Carglumic acid, Cilastatin, Citiolone, Coprine, Dibromotyrosine, Dihydroxyphenylglycine, Eflornithine, Fenclonine, 4-Fluoro-L-threonine, N-Formylmethionine, Gamma-L-Glutamyl-L-cysteine, 4-(?-Glutamylamino)butanoic acid, Glutaurine, Glycocyamine, Hadacidin, Hepapressin, Lisinopril, Lymecycline, N-Methyl-D-aspartic acid, N-Methyl-L-glutamic acid, Milacemide, Nitrosoproline, Nocardicin A, Nopaline, Octopine, Ombrabulin, Opine, Orthanilic acid, Oxaceprol, Polylysine, Remacemide, Salicyluric acid, Silk amino acid, Stampidine, Tabtoxin, Tetrazolylglycine, Thiorphan, Thymectacin, Tiopronin, Tryptophan tryptophylquinone, Valaciclovir, Valganciclovir, and combinations thereof;
and
d) polishing the surface of the semiconductor substrate to selectively remove the first material;
wherein Co is a metal inter-connection material; at least a portion of the surface is in contact with both the polishing pad and the chemical mechanical polishing composition; and ratio of removal rate of the first material to removal rate of the second material is greater than 1.
US Pat. No. 10,214,573

BIGLYCAN VARIANT POLYPEPTIDES AND METHODS OF USE

Tivorsan Pharmaceuticals,...

1. A composition comprising a biglycan variant polypeptide lacking glycosaminoglycan side chains, wherein the biglycan variant polypeptide consists essentially of a monomeric form of a biglycan variant polypeptide that has an amino acid sequence as set forth in amino acid residues 38-368 of SEQ ID NO: 4 and a molecular weight of approximately 40-44 kDa and potentiates at least 50% of maximal agrin-induced acetylcholine receptor (AChR) clustering at a concentration of biglycan variant polypeptide from about 0.016 to 0.512 ?g/ml.
US Pat. No. 10,216,109

ELECTROSTATIC LATENT IMAGE DEVELOPING TONER AND PRODUCTION METHOD OF THE SAME

KYOCERA Document Solution...

1. An electrostatic latent image developing toner comprisinga plurality of toner particles each including a toner core and a shell layer covering a surface of the toner core, wherein
the shell layer contains a hydrophobic thermoplastic resin and a positively chargeable hydrophilic water-insoluble resin, and
an existing amount A of alkali metal elements present in a surface layer of the shell layer measured by X-ray photoelectron spectroscopy and an existing amount B of alkali metal elements present in each of the toner particles as a whole measured by fluorescent X-ray analysis satisfy expressions (a) and (b) shown below
A?300 ppm  (a)
0.5?A/B<1.0  (b).
US Pat. No. 10,214,574

ENGINEERED CALMODULIN FOR TREATMENT OF RYANOPATHIES

Ohio State Innovation Fou...

1. An isolated polypeptide comprising the amino acid sequence SEQ ID NO:1 having at least one mutation selected from the group consisting of F13Q, T27D, T29D, M37Q, L40Q, N61D, M72Q, and M73Q.
US Pat. No. 10,216,110

TONER BINDER AND TONER

Sanyo Chemical Industries...

1. A toner binder comprising a polyester resin, wherein the toner binder satisfies Formula (1) and Formula (2) given below and has a content of a surfactant of 100 ppm or less,G?x150?10,000  (1)
G?x150/G?y150?500  (2)
wherein G?x150 represents the storage modulus (unit: Pa) at 150° C. for the tetrahydrofuran (THF)-insoluble component of the toner binder and G?y150 represents the storage modulus (unit: Pa) at 150° C. of the THF-soluble component of the toner binder,
wherein the polyester resin comprises a non-linear polyester resin (A) and a and a linear polyester resin (B),
and wherein the non-linear polyester resin (A) is either:
(i) a modified non-linear polyester resin (A1) produced by reacting a polyester resin (a1) having an active hydrogen on a terminal of the main chain with an extender (D) wherein the extender (D) is a radical reaction initiator (D2),
(ii) a modified non-linear polyester resin (A2) prepared by chemically bonding a polyester resin (a2) prepared from an alcohol component (y) and an unsaturated carboxylic acid component (z) with a carbon-carbon linkage between resin molecules by a radical addition reaction under the existence of a radical reaction initiator (D2), or
(iii) a modified non-linear polyester resin (A3) prepared by chemically bonding a polyester resin (a2) prepared from an alcohol component (y) and an unsaturated carboxylic acid component (z) with a compound (b) having a radical reactive group and having a number average molecular weight of 1,000 or less by a radical addition reaction under the existence of a radical reaction initiator (D2).
US Pat. No. 10,214,575

PROCESS FOR THE PURIFICATION OF A GROWTH FACTOR PROTEIN

OCTAPHARMA AG, Lachen (C...

1. A process of purifying a Growth Factor Protein Granulocyte Colony Stimulating Factor (G-CSF) in a purification sequence employing chromatography comprising:performing at least one chromatography step using a multimodal resin which comprises a negatively charged 2-(benzoylamino) butanoic acid ligand,
binding the G-CSF to the multimodal resin at a pH from 4 to 6.2, and
eluting the G-CSF at a pH in the range of from 5.5 to 6.5, wherein the elution is performed with an arginine buffer having a concentration in the range of from 0.1 M to 2.0 M,
optionally in combination with an affinity ligand chromatography step wherein the affinity ligand is a yeast derived Fab fragment directed toward the G-CSF.
US Pat. No. 10,216,111

ANTIMICROBIAL SULFONATED POLYESTER RESIN

Xerox Corporation, Norwa...

1. An antimicrobial core-shell resin particle comprising (a) a core comprising a sulfonated polyester resin and a nanoparticle, and (b) a shell on said core comprising a nanoparticle, wherein the nanoparticles of said core and shell comprise silver in a form selected from the group consisting of a silver salt, a silver composite and elemental silver, and further wherein the resin particle has a D50 mass median diameter of about 5 nm to about 500 nm.
US Pat. No. 10,214,576

ANTIGEN-SPECIFIC HELPER T-CELL RECEPTOR GENES

International Institute o...

1. A method for the treatment of a WT1-expressing cancer in a subject, comprising introducing a CD4+ helper T-cell into the subject,wherein the CD4+ helper T cell is obtained by introducing a TCR gene into a CD4+ T cell, wherein
(i) the TCR gene comprises a pair of polynucleotides chosen from:
(a) SEQ ID NO: 1 and SEQ ID NO: 2;
(b) SEQ ID NO: 3 and SEQ ID NO: 4;
(c) SEQ ID NO: 5 and SEQ ID NO: 6;
(d) SEQ ID NO: 3 and SEQ ID NO: 7;
(e) SEQ ID NO: 8 and SEQ ID NO: 9;
(f) SEQ ID NO: 10 and SEQ ID NO: 12;
(g) SEQ ID NO: 11 and SEQ ID NO: 12;
(h) SEQ ID NO: 13 and SEQ ID NO: 15,
(i) SEQ ID NO: 14 and SEQ ID NO: 15;
(j) SEQ ID NO: 16 and SEQ ID NO: 17;
(k) SEQ ID NO: 18 and SEQ ID NO: 19;
(l) SEQ ID NO: 20 and SEQ ID NO: 21;
(m) SEQ ID NO: 22 and SEQ ID NO: 24;
(n) SEQ ID NO: 23 and SEQ ID NO: 24;
(o) SEQ ID NO: 25 and SEQ ID NO: 26;
(p) SEQ ID NO: 27 and SEQ ID NO: 4;
(q) SEQ ID NO: 28 and SEQ ID NO: 29;
(r) SEQ ID NO: 30 and SEQ ID NO: 32;
(s) SEQ ID NO: 31 and SEQ ID NO: 32;
(t) SEQ ID NO: 33 and SEQ ID NO: 34;
(u) SEQ ID NO: 35 and SEQ ID NO: 36;
(v) SEQ ID NO: 37 and SEQ ID NO: 38;
(w) SEQ ID NO: 39 and SEQ ID NO: 40;
(x) SEQ ID NO: 41 and SEQ ID NO: 42;
(y) SEQ ID NO: 43 and SEQ ID NO: 44;
(z) SEQ ID NO: 45 and SEQ ID NO: 46;
(aa) SEQ ID NO: 47 and SEQ ID NO: 48;
(bb) SEQ ID NO: 49 and SEQ ID NO: 50;
(cc) SEQ ID NO: 51 and SEQ ID NO: 52;
(dd) SEQ ID NO: 53 and SEQ ID NO: 54;
(ee) SEQ ID NO: 55 and SEQ ID NO: 57;
(ff) SEQ ID NO: 56 and SEQ ID NO: 57; and
(gg) SEQ ID NO: 58 and SEQ ID NO: 59; or
(ii) the TCR gene comprises a pair of polynucleotides that are complementary to or degenerate of any of the pairs of polynucleotides listed in (i).
US Pat. No. 10,214,321

CONTAINER FOR A CONSUMABLE GOOD, COATED WITH A RESVERATROL CONTAINING LAYER

Barokes, PTY LTD, Victor...

1. A container for a consumable good wherein an inner surface of the container is at least partially coated with a coating layer comprising resveratrol.
US Pat. No. 10,214,577

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has a cancer overexpressing a LAMB3 polypeptide comprising the amino acid sequence of SEQ ID NO: 11, comprising administering to said patient a population of activated T cells that kill the cancer cells,wherein the activated T cells are antigen-specific CD8+ cytotoxic T cells produced by contacting CD8+ T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 11 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro,
wherein said cancer is selected from the group consisting of esophageal cancer, lung cancer, melanoma, uterine cancer, hepatocellular cancer, gallbladder cancer, and bile duct cancer.
US Pat. No. 10,216,113

ROLLER FOR IMAGE FORMING APPARATUS

HP PRINTING KOREA CO., LT...

1. A roller for an image forming apparatus comprising:a shaft;
an elastic layer covering an outer circumference of the shaft; and
a coating layer formed on the elastic layer, the coating layer including acryl polyol and ?-caprolactone polyol in a mixture cross-linked by isocyanate.
US Pat. No. 10,214,578

VARIANTS OF IGG-FC FUSION THAT PROVIDE FOR SITE-SPECIFIC CONJUGATION AT THE N-TERMINUS

1. A molecule comprising a conjugated, lysine-depleted variant of an immunoglobulin G Fc (IgG-Fc-LDV) domain, comprising an amino acid sequence of IgG-Fc wherein all of the native lysine residues have been replaced with a different amino acid residue selected from the group of amino acids that excludes cysteine, methionine, proline and lysine, and wherein said IgG-Fc-LDV is conjugated in a site specific manner at its N-terminus with a polymeric molecule.
US Pat. No. 10,214,579

FC FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS

BRISTOL-MYERS SQUIBB COMP...

1. An isolated nucleic acid sequence encoding a polypeptide comprising an immunoglobulin Fc domain and a heterologous polypeptide, wherein the heterologous polypeptide is fused to the N-terminus or the C-terminus of the Fc domain by a polypeptide linker, wherein the polypeptide linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 51-54, 63-65, and 84.
US Pat. No. 10,214,580

CONSTRUCTS AND LIBRARIES COMPRISING ANTIBODY SURROGATE LIGHT CHAIN SEQUENCES

I2 PHARMACEUTICALS, INC.,...

1. A tetrameric construct comprising:(a) a first and a second surrogate light chain fusion polypeptide, each comprising the amino acid sequence of SEQ ID NO: 10, and;
(b) a first and a second antibody heavy chain polypeptide comprising, from N-terminus to C-terminus, a heavy chain variable region (VH), a heavy chain first constant region (CH1), a hinge region, a heavy chain second constant region (CH2), and a heavy chain third constant region (CH3), wherein each antibody heavy chain polypeptide comprises the amino acid sequence of SEQ ID NO: 9,
wherein the first surrogate light chain fusion polypeptide is non-covalently conjugated to the first antibody heavy chain polypeptide, wherein the second surrogate light chain fusion polypeptide is non-covalently conjugated to the second antibody heavy chain polypeptide, and wherein the construct is capable of specifically binding to a target, wherein the target is an influenza A virus.
US Pat. No. 10,214,581

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS

XBIOTECH, INC., Vancouve...

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody which specifically binds Staphylococcus aureus protein A (SpA) with a KD of less than 1×10?10 M via its Fab region paratope, wherein the monoclonal antibody is able to displace human IgG immunoglobulins bound to SpA on Staphylococcus aureus bacteria via their Fc regions, wherein the monoclonal antibody specifically binds to an amino acid sequence selected from the group of amino acid sequences consisting of SEQ ID NO: 1, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85.
US Pat. No. 10,214,582

ANTI-CGRP COMPOSITIONS AND USE THEREOF

ALDERBIO HOLDINGS LLC, L...

1. A method of treating, preventing, ameliorating, or reducing pain in a patient experiencing pain or comprising a pain-associated disorder, by administering to said patient an effective amount of a pharmaceutical composition comprising a humanized anti-calcitonin gene related peptide (CGRP) antibody comprising a variable light (VL) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57, and a variable heavy (VH) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3 of SEQ ID NO: 58, SEQ ID NO: 59, and SEQ ID NO: 60.
US Pat. No. 10,214,838

HIGH MODULUS SINGLE TWISTED NYLON 6.6 YARNS

1. A dipped and heat-set polyamide 6.6 single twisted yarn, comprising a raw polyamide 6.6 yarn having a tensile stress value of greater than 1.30 cN/dtex at 4% elongation;wherein a tensile stress value of the single twisted yarn at 4% elongation is greater than 2.0 cN/dtex and less than 2.8 cN/dtex,
wherein a heat shrinkage of the single twisted yarn is greater than 4.0% and less than 7.0% determined at 177° C. under 0.045 g/dtex pretension with 2 minutes exposure time;
wherein the tensile stress values are determined with a tensile tester according to ASTM D885-16;
wherein the single twisted yarn is twisted strand.
US Pat. No. 10,214,583

SODIUM PUMP ANTIBODY AGONISTS AND METHODS OF TREATING HEART DISEASE USING THE SAME

1. A method of producing a positive inotropic effect in a mammalian host, comprises administering to said mammalian host an immunogenic formulation comprising (i) a therapeutically effective amount of one or more synthetic peptides selected from the group consisting of SEQ ID NOS: 3 and 4; (ii) a pharmaceutically acceptable carrier and adjuvant, wherein said immunogenic formulation induces endogenous production of antibodies that specifically bind to epitopes of the ?1 subunit of the (Na++K+)-ATPase (NKA) and have NKA agonist activity.
US Pat. No. 10,214,584

THERAPEUTIC PHARMACEUTICAL COMPOSITION EMPLOYING ANTI-SLC6A6 ANTIBODY

ORDER-MADE MEDICAL RESEAR...

1. A monoclonal antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds SLC6A6, wherein the monoclonal antibody is at least one selected from the group consisting of:(a) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 125 in SEQ ID NO: 24 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 44 to 54, positions 70 to 76 and positions 109 to 116 in SEQ ID NO: 26 as light chain CDR1, CDR2 and CDR3, respectively;
(b) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 126 in SEQ ID NO: 28 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 46 to 57, positions 73 to 79 and positions 112 to 119 in SEQ ID NO: 30 as light chain CDR1, CDR2 and CDR3, respectively;
(c) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 128 in SEQ ID NO: 32 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 48 to 58, positions 74 to 80 and positions 113 to 120 in SEQ ID NO: 34 as light chain CDR1, CDR2 and CDR3, respectively;
(d) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 131 in SEQ ID NO: 36 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 44 to 54, positions 70 to 76 and positions 109 to 116 in SEQ ID NO: 38 as light chain CDR1, CDR2 and CDR3, respectively;
(e) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 129 in SEQ ID NO: 40 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 44 to 54, positions 70 to 76 and positions 109 to 116 in SEQ ID NO: 42 as light chain CDR1, CDR2 and CDR3, respectively; and
(f) an antibody which comprises a heavy chain variable region comprising amino acid sequences located at positions 50 to 54, positions 69 to 86 and positions 118 to 126 in SEQ ID NO: 44 as heavy chain CDR1, CDR2 and CDR3, respectively, and a light chain variable region comprising amino acid sequences located at positions 46 to 57, positions 73 to 79 and positions 112 to 119 in SEQ ID NO: 46 as light chain CDR1, CDR2 and CDR3, respectively.
US Pat. No. 10,214,585

REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS

Yeda Research and Develop...

1. A method of treating an Alzheimer's Disease, the method comprising administering to an individual in need thereof a composition comprising a neutralizing antibody against a programmed death ligand 1 (PD-L1), or an anti-PD-L1 antibody fragment thereof having antagonistic or inactivating activity,wherein the composition is administered by a dosage regime comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session where the composition is administered once to the individual followed by a non-treatment period of 14 days or longer where the composition is not administered to the individual,
wherein administration of the composition transiently reduces levels of systemic immunosuppression and increases choroid plexus gateway activity in facilitating selective recruitment of immune cells into the central nervous system, thereby treating the individual.
US Pat. No. 10,213,818

METHOD FOR PREPARING HOT-ROLLED SEMIFINISHED STEEL ROLLED STOCK FOR COLD ROLLING

1. A method of removing scale from hot-rolled steel stock in preparation for cold rolling of the stock, the method comprising:preliminary cold rolling the stock having a width up to 2000 mm in mill rolls having polished working surfaces using (i) a reduction of 12 to 35% and (ii) a 3.8±0.5%/mm ratio of the reduction to a length of a deformation region of the stock;
applying spindle oil between surfaces of the stock and the working surfaces of the mill rolls; and
straightening the stock after the cold rolling of the stock.
US Pat. No. 10,214,586

PD-L1 ANTIBODIES

Eli Lilly and Company, I...

1. An antibody that binds human PD-L1 (SEQ ID NO: 1), comprising a light chain (LC) and a heavy chain (HC), wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), and wherein the LCVR comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 consisting of the amino acid sequences SGSSSNIGSNTVN (SEQ ID NO: 5), YGNSNRPS (SEQ ID NO: 6), and QSYDSSLSGSV (SEQ ID NO: 7), respectively, and wherein the HCVR comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 consisting of the amino acid sequences KASGGTFSSYAIS (SEQ ID NO: 2), GIIPIFGTANYAQKFQG (SEQ ID NO: 3), and ARSPDYSPYYYYGMDV (SEQ ID NO: 4), respectively.
US Pat. No. 10,214,587

DEPLETION OF PLASMACYTOID DENDRITIC CELLS

The University of North C...

1. A method of depleting plasmacytoid dendritic cells (pDC) in a subject, comprising delivering to the subject an effective amount of an antibody or a fragment thereof that specifically binds to blood dendritic cell antigen-2 (BDCA2) and depletes pDC, thereby depleting pDC;wherein the antibody or a fragment thereof comprises a heavy chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6; and/or
the antibody or a fragment thereof comprises a light chain variable region comprising the three complementarity determining regions of the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:8.
US Pat. No. 10,214,589

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING

GENZYME CORPORATION, Cam...

1. An isolated polynucleotide encoding a binding polypeptide comprising at least one modified glycan comprising at least one moiety of Formula (IV):-Gal-Sia-C(H)?N-Q-CON-X   Formula (IV),
wherein:
A) Q is NH or O;
B) CON is a connector moiety;
C) X is a diagnostic or therapeutic effector moiety;
D) Gal is a galactose moiety; and
E) Sia is a sialic acid moiety.
US Pat. No. 10,214,590

INHIBITORS OF ENDOGLIN ACTIVITY FOR THE TREATMENT OF FIBROSIS

Tufts Medical Center, Inc...

1. A method of treating a fibrotic disease in a human subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a composition comprising an antibody or antigen-binding fragment thereof that binds endoglin and inhibits endoglin activity, wherein the fibrotic disease is selected from the group consisting of lung fibrosis, kidney fibrosis, and liver fibrosis.
US Pat. No. 10,216,895

RARE VARIANT CALLS IN ULTRA-DEEP SEQUENCING

Roche Molecular Systems, ...

1. A computer-implemented method of detecting low frequency variants in a target region in a first sample, the method comprising, using a computer system:sequencing DNA fragments from one or more samples, the one or more samples including the first sample, wherein the sequencing includes targeting the target region in the DNA fragments, and wherein the sequencing is associated with an error rate;
receiving a plurality of sequence reads obtained from sequencing the DNA fragments from the one or more samples;
aligning the plurality of sequence reads to the target region of a reference sequence;
identifying a first candidate variant having a first allele at a first location of the target region based on sequence reads of the first sample differing from a reference allele at the first location of the reference sequence;
determining a first variant frequency for the first allele at the first location based on sequence reads of the first sample that align to the first location of the reference sequence, wherein the first variant frequency is equal to or lower than the error rate;
identifying the first candidate variant as corresponding to a first variant class selected from a plurality of variant classes, each variant class of the plurality of variant classes corresponding to a different type of variant;
identifying a set of second locations in the target region of the reference sequence that have the reference allele, wherein at least 50% of the other locations in the one or more samples exhibit a false positive for the first allele, and wherein the set of second locations includes the first location;
at each of the set of second locations and for each of the one or more samples:
determining a second variant frequency of the first allele based on sequence reads of the sample that align to the second location of the reference sequence, the second variant frequencies forming a statistical distribution;
comparing the first variant frequency to a statistical value of the statistical distribution to determine a probability value of the first variant frequency relative to the statistical value of the statistical distribution; and
determining whether the first candidate variant is a true positive in the first sample for the first allele by comparing the probability value to a threshold value, the threshold value differentiating between false positives and true positives for the first allele.
US Pat. No. 10,213,311

DEFORMABLE ARTICULATING TEMPLATES

ZIMMER INC., Warsaw, IN ...

1. A system for generating a patient-specific implant, the system comprising:a means for generating a three-dimensional electronic representation of a human anatomical feature including size and curvature features matching the human anatomical feature;
a means for selecting a virtual implant template from a database of virtual implant templates generated by a means for generating a series of the virtual implant templates;
a means for designing a patient-specific prosthetic implant to imitate the size and curvature features based at least in part on the selected virtual implant template; and
a means for virtually testing fit of the patient-specific prosthetic implant using the three-dimensional electronic representation of the human anatomical feature.
US Pat. No. 10,214,591

MONOCLONAL ANTIBODY TO HUMAN LINE-1 ORF2 PROTEIN AND METHOD FOR EARLY DETECTION OF TRANSFORMING CELLS IN PRE-NEOPLASTIC TISSUES OF A HUMAN SUBJECT

1. A monoclonal antibody which specifically binds to human Long Interspersed Element-1 Open Reading Frame 2p (L1-ORF2p) obtained from hybridoma ChA1-L1 deposited under the Budapest Treaty on Dec. 2, 2014, under accession number 14120202 at the European Collection of Cell Cultures (Culture Collections Public Health England, Porton Down Salisbury Wiltshire, SP40JG).
US Pat. No. 10,214,592

PROTEIN ASSAY METHOD SPECIFIC TO TRACP-5B (TARTRATE RESISTANT ACID PHOSPHATASE 5B)

NITTO BOSEKI CO., LTD., ...

1. A monoclonal antibody which recognizes an epitope based on a steric structure of TRACP-5b (Tartrate-Resistant Acid Phosphatase 5b); which does not recognize any of epitopes formed of a primary structure of linear sequence of TRACP-5b; and which does not bind to TRACP-5a (Tartrate-Resistant Acid Phosphatase 5a), wherein said antibody is produced by Hybridoma TrK-126 of Accession number NITE BP-01866 or Hybridoma TrK-127 of Accession number NITE BP-01867.
US Pat. No. 10,216,897

CONSTRUCTION OF DIVERSE SYNTHETIC PEPTIDE AND POLYPEPTIDE LIBRARIES

I2 PHARMACEUTICALS, INC.,...

1. A method of making a library of antibody heavy or light chains, comprising the steps of(a) aligning a plurality of antibody heavy or light chain sequences comprising one or more CDR sequence motifs;
(b) creating a first dataset by applying a predetermined combination of two or more filters based on parameters of said antibody heavy or light chain sequences;
(c) analyzing said first dataset for positional amino acid usage frequency within at least one of said CDR sequence motifs;
(d) creating a second dataset characterized by a minimum threshold amino acid usage frequency at one or more amino acid positions within said CDR sequence motif; and
(e) synthesizing an antibody heavy or light chain library designed with the aid of the first and second datasets identified, by generating a discrete number of defined or degenerate oligonucleotides such that only defined amino acids are generated.
US Pat. No. 10,214,593

ANTI-IDIOTYPE ANTIBODY AGAINST ANTI-C-MET ANTIBODY

SAMSUNG ELECTRONICS CO., ...

1. An anti-idiotype antibody or antigen-binding fragment thereof that specifically binds to an idiotype of an anti-c-Met antibody comprising:(a) a CDR-H1 comprising the amino acid sequence of SEP ID NO: 116, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 140, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 156, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 173, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 189;
(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 125, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 155, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 172, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 188;
(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 117, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 127, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 141, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 157, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 174, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 190;
(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 118, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 142, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 158, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 175, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 191;
(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 117, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 143, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 159, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 176, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 192;
(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 118, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 130, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 144, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 160, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 177, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 193;
(g) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 131, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 145, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 178, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 191;
(h) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 116, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 132, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 146, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 162, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 178, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 194;
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 119, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 147, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 163, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 179, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 189;
(j) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 119, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 148, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 164, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 180, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 195; or
(k) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 120, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 149, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 165, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 181, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 196.
US Pat. No. 10,216,898

BIOINFORMATICS SYSTEMS, APPARATUSES, AND METHODS EXECUTED ON AN INTEGRATED CIRCUIT PROCESSING PLATFORM

Edico Genome Corporation,...

1. A system for executing a sequence analysis on a plurality of reads of genomic data using an index of genetic reference data stored in a memory, each read of genomic data representing a sequence of nucleotides, the genetic reference data representing one or more genetic reference sequences, the system comprising:a cloud-based server; and
an integrated circuit connected with the cloud-based server, the integrated circuit being formed of a set of pre-configured hardwired digital logic circuits that are interconnected by a plurality of physical electrical interconnects, one or more of the plurality of physical electrical interconnects comprising a memory interface for the integrated circuit to access the memory, the hardwired digital logic circuits being arranged as a set of processing engines, each processing engine being formed of a subset of the hardwired digital logic circuits to perform one or more steps in the sequence analysis on the plurality of reads of genomic data, the set of processing engines comprising a mapping module in a first hardwired configuration to:
receive a read of genomic data via one or more of the plurality of physical electrical interconnects;
extract a portion of the read to generate a seed, the seed representing a subset of the sequence of nucleotides represented by the read;
calculate a first address within the index based on the seed;
access the address in the index in the memory;
receive a record from the address, the record representing position information in the genetic reference sequence;
determine, based on the record, one or more matching positions from the read to the genetic reference sequence; and
output, to the cloud-based server, at least one of the matching positions to the memory via the memory interface.
US Pat. No. 10,214,595

NANOCELLULOSE COMPOSITIONS AND PROCESSES TO PRODUCE SAME

API Intellectual Property...

1. A composition comprising hydrophobic nanocellulose and lignin, wherein hydrophobicity of said nanocellulose arises from said lignin, wherein said nanocellulose contains about 0.5 wt % sulfur content or less, and wherein said nanocellulose is characterized by a crystallinity of at least 60%.
US Pat. No. 10,214,596

CHITIN NANOCRYSTALS AND PROCESS FOR PREPARATION THEREOF

1. A process for producing chitin nanocrystals (ChNCs) comprising contacting a chitinous material with a sufficient amount of an inorganic persulfate to produce chitin nanocrystals from the chitinous material.
US Pat. No. 10,214,341

AEROSOL PRODUCT FOR FORMING COOLING GEL COMPOSITION FOR HUMAN BODY

Toyo Aerosol Industry Co....

1. An aerosol product for forming a cooling gel composition for a human body, comprising:a double-structure container including a propellant filling space and two independent liquid concentrate filling spaces and having a discharging mechanism for simultaneously discharging contents of the two liquid concentrate filling spaces, wherein
the propellant filling space in the double-structure container comprises a propellant composed of a compressed gas,
a first liquid concentrate filling space of the two independent liquid concentrate filling spaces in the double-structure container is filled with a first liquid concentrate composition, and a second liquid concentrate filling space of the two independent liquid concentrate filling spaces in the double-structure container is filled with a second liquid concentrate composition,
the first liquid concentrate composition contains a hydrated endothermic substance dispersed in a liquid medium composed of a solvent containing a viscosity modifier and has a viscosity of 1,000 to 125,000 mPa·s at a temperature of 20° C., the hydrated endothermic substance contained in the first liquid concentrate composition comprises at least one selected from the group consisting of xylitol, sorbitol, erythritol, maltitol, lactitol, mannitol, and palatinit, a content ratio of the hydrated endothermic substance in the first liquid concentrate composition is 1% to 30% by mass per 100% by mass of the first liquid concentrate composition, a content ratio of the solvent in the first liquid concentrate composition is 60% by mass or more per 100% by mass of the first liquid concentrate composition, a content ratio of the viscosity modifier in the first liquid concentrate composition is 0.05% to 10% by mass per 100% by mass of the first liquid concentrate composition;
the second liquid concentrate composition contains water and a viscosity modifier and has a viscosity of 1,000 to 125,000 mPa·s at a temperature of 20° C., a content ratio of water in the second liquid concentrate composition is 49.8% to 95% by mass per 100% by mass of the second liquid concentrate composition, a content ratio of the viscosity modifier in the second liquid concentrate composition is 0.05% to 5% by mass per 100% by mass of the second liquid concentrate composition, and
the first liquid concentrate composition discharged from the first liquid concentrate filling space and the second liquid concentrate composition discharged from the second liquid concentrate filling space are mixed to form a cooling gel composition for the human body.
US Pat. No. 10,214,853

TEXTILE PRINTING PAPER FOR USE IN PAPER PRINTING METHOD

MITSUBISHI PAPER MILLS LI...

1. A textile printing paper for use in a paper printing method involving performing dye fixing treatment in such a state that a printed paper is kept stuck to a printing substrate, the textile printing paper comprising a base paper and a glue layer on a surface of the base paper, whereinthe glue layer functions as an ink receiver, as an adhesive layer for adhering the printed paper to the printing substrate, and as a release layer,
the base paper has a sizing degree of 10 to 40 g/m2 as measured according to JIS P 8140:1998, and
the glue layer comprises at least one water-soluble synthetic binder and a natural glue, and
at least one of the water-soluble synthetic binders is a water-soluble polyester binder with a glass transition temperature of 51° C. or higher.
US Pat. No. 10,214,855

METHOD FOR MAKING MODIFIED CELLULOSE PRODUCTS

UPM-KYMMENE CORPORATION, ...

1. A method for making modified cellulose products, comprisingprocessing cellulose pulp to modified cellulose pulp at a manufacturing location to increase the susceptibility of fibers to disintegration,
setting the modified cellulose pulp to a suitable dry matter content, and
transporting the modified cellulose pulp at set dry matter content to a location of use, which is a different location from the manufacturing location, where the modified cellulose pulp is disintegrated to nanofibrillar cellulose, wherein the dry matter content of the modified cellulose pulp is set to 20-60%.
US Pat. No. 10,214,601

NON-STRETCHED POLYPROPYLENE-BASED FILM

LG Chem, Ltd., Seoul (KR...

1. A non-stretched polypropylene-based film comprising a propylene-ethylene-1-butene terpolymer which has a melting point (Tm) of 125 to 135° C., a molecular weight distribution (Mw/Mn, PDI) of 2.3 to 3.5, and a xylene soluble (Xs) content of 2.0 wt° or less,wherein the terpolymer has a crystallization temperature (Tc) of 75 to 87° C.,
wherein the terpolymer has MFR2,16(g/10 min, measured at 230° C. according to ASTM1238) of 5 to 7, and
wherein, when heat-sealed at 134° C. and 0.2 MPa for 1 second, a sealing strength of the terpolymer is 300 to 500 g/15mm.
US Pat. No. 10,215,882

TAGGED CHEMICAL DIVERTER

CARBO CERAMICS INC., Hou...

1. A method for detecting diverter material placed in a borehole region, comprising:(a) obtaining a first data set by:
(i) lowering into a borehole traversing the borehole region a pulsed neutron logging tool comprising a pulsed neutron source and a detector,
(ii) emitting pulses of neutrons from the pulsed neutron source into the borehole region,
(iii) detecting capture gamma rays resulting from nuclear reactions in the borehole region;
(b) placing a diverter material comprising aqueous-swellable particles and a thermal neutron absorbing material into the borehole region;
(c) obtaining a second data set by:
(i) emitting pulses of neutrons from the first pulsed neutron source or a second pulsed neutron source into the borehole region,
(ii) detecting capture gamma rays in the borehole; and
(d) comparing the first data set and the second data set to determine the location of diverter material placed in the borehole region.
US Pat. No. 10,213,579

CATHETER FOR CELL INFUSION AND METHOD OF PRESSURE REGULATION

SciCoTec GmbH, Gruenwald...

1. A method of injecting stem cells obtained from body tissue of a human donor subject to be engrafted at a predetermined target site of damaged or failing tissue of a recipient subject for repair or replacement of such tissue, including the steps of:selecting a balloon catheter having a central lumen open at both ends and characterized by two different interconnected diameters for use in the cell infusion, including a central lumen diameter size and outer diameter length distal portion relatively smaller than the central lumen diameter size and shorter than the outer diameter length of the proximal portion, such that a constriction is formed in the central lumen at the junction between the proximal and distal portions of the catheter, the distal portion outer diameter length being selected to enable its entry into a natural vessel or duct of smaller lumen diameter to the target site while the proximal portion is navigable through natural vessels or ducts of larger lumen diameter leading to but unnavigable into such smaller lumen diameter natural vessel or duct in the body of the recipient subject;
inserting the distal portion end of the catheter for advancement through the system of natural vessels or ducts of the recipient subject's body to position the central lumen opening at the tip of the catheter at the distal portion end in proximity to the target site;
inflating the catheter's balloon located rearward of the opening at the catheter tip to block antegrade natural fluid flow in the natural vessel or duct at the target site while the catheter is in said position;
while the antegrade blockage is maintained, introducing under adjustable pressure into the central lumen opening at the proximal portion end of the catheter a volume of biocompatible fluid containing a predetermined quantity of the stem cells nominally of sizes larger than diameters of capillaries of the capillary bed in the natural vessel or duct at the target site, sensing sudden increase in resistant pressure indicative of obstruction to automatically increase the level of ejection pressure to overcome resistant pressure from the smaller central lumen diameter of the catheter's distal portion and buildup of cells in the fluid flow at the catheter tip and occlusion of the smaller capillaries, for an interval of time sufficient to clear the obstruction and thereupon reduce the ejection pressure to a level sufficient to allow concentration of at least a substantial percentage of the predetermined quantity of the introduced cells to enter and remain in the natural vessel or duct at the target site so as to infiltrate the tissue to be repaired or replaced underlying an endothelial barrier of the capillary bed when ejected from the central lumen opening at the catheter tip, rather than being forced by excessive ejection pressure rapidly away from the capillary bed thereat, the central lumen diameter sizes of the proximal and distal portions of the catheter being selected to produce increasing velocity and reduced pressure drop of cell flow through the catheter's central lumen at said constriction, and the inflated balloon serving as well to block retrograde flow of ejected cells through the natural vessel or duct from the target site;
monitoring the ejection pressure and adjusting the pressure at which the fluid containing the cells is introduced accordingly, so as to maintain said sufficient level of ejection pressure and thereby force the cells to undergo extravasation through the endothelial barrier for infiltration into underlying damaged or failing tissue at the target site toward achieving repair or replacement thereof; and
ceasing carrier fluid introduction, deflating the balloon, and removing the catheter from the recipient subject's body to enable restoration of natural fluid flow at the target site before an occurrence of underlying tissue damage.
US Pat. No. 10,214,603

POLYETHYLENE COMPOSITIONS AND METHODS OF MAKING AND USING SAME

Chevron Phillips Chemical...

1. A polyolefin having a long chain branching distribution per molecule in a range of from about 0 to about 20 at a Mw of the polyolefin ranging from about 1.00E+05 g/mol to about 3.00E+06 g/mol which when extruded at a temperature in a range of from about 590° F. to about 645° F. and then coated onto a substrate at a rate of from about 300 ft/min to about 1000 ft/min has an edge weave of from about 0 in/side to about 2.5 in/side and a neck-in of less than about 3.0 in/side.
US Pat. No. 10,214,604

VINYL ALCOHOL POLYMER AND USE THEREOF

KURARAY CO., LTD., Kuras...

1. A vinyl alcohol-based polymer having an ethylenic double bond with a saponification degree of 70 mol % or more, whereinthe vinyl alcohol-based polymer is water-soluble;
a molar ratio of the ethylenic double bond to a total of vinyl alcohol units and vinyl acetate units is 0.05/100 to 2/100; and
a limiting viscosity [?] and a weight-average molecular weight Mw of a vinyl ester-based polymer which is produced by esterifying the vinyl alcohol-based polymer satisfy formulas (1) and (2):
4.7?log Mw?6.3  (1)
0.60<(log [?]+3.75)/log Mw<0.69  (2).
US Pat. No. 10,213,837

TITANIUM POWDER CONTAINING SOLID-SOLUTED NITROGEN, TITANIUM MATERIAL, AND METHOD FOR PRODUCING TITANIUM POWDER CONTAINING SOLID-SOLUTED NITROGEN

HI-LEX CORPORATION, Hyog...

1. A method for producing titanium powder containing a solid-soluted nitrogen, the method comprising:heating titanium powder comprising titanium particles in a nitrogen-containing atmosphere to dissolve nitrogen atoms and form a solid solution of nitrogen atoms in a matrix of the titanium particles,
wherein
a heating temperature for forming the solid solution of the nitrogen atoms in the matrix of the titanium particles is 400° C. or more and 600° C. or less, and
the heating causes the titanium particles to have a nitrogen content of 0.1 mass % or more and 0.65 mass % or less.
US Pat. No. 10,214,605

METHOD FOR PRODUCING POLYCARBOXYLIC ACID POLYMER

NIPPON SHOKUBAI CO., LTD....

1. A method of producing a polycarboxylic acid-based polymer, comprising adding a monomer composition containing (meth)acrylic acid and/or salts thereof, a monomer composition containing maleic acid and/or salts thereof, a monomer composition containing (meth)acrylic acid and/or salts thereof and a sulfonic group-containing compound, a monomer composition containing maleic acid and/or salts thereof and a sulfonic group-containing compound, or a monomer composition containing (meth)acrylic acid and/or salts thereof, maleic acid and/or salts thereof and a sulfonic group-containing compound to a reaction vessel to perform a polymerization reaction,wherein the polycarboxylic acid-based polymer is a homopolymer of poly(meth)acrylic acid and/or salts thereof, a homopolymer of polymaleic acid and/or salts thereof, a copolymer of (meth)acrylic acid and/or salts thereof and a sulfonic group-containing compound, a copolymer of maleic acid and/or salts thereof and a sulfonic group-containing compound, or a copolymer of (meth)acrylic acid and/or salts thereof, maleic acid and/or salts thereof and a sulfonic group-containing compound,
the method further comprising adding a defoaming agent by a time when 100 mass % of a total amount of the monomer composition is added.
US Pat. No. 10,218,194

LITHIUM-BASED BATTERY PACK FOR A HAND HELD POWER TOOL

MILWAUKEE ELECTRIC TOOL C...

1. A battery pack comprising:a housing connectable to and supportable by a hand held power tool;
a plurality of battery cells supported within the housing, the plurality of battery cells connected in a combined series-parallel configuration, each of the plurality of battery cells having a lithium-based chemistry, each of the plurality of battery cells being cylindrical and having a cell diameter and a cell length, the cell length being at least about two times the cell diameter;
first and second terminals for electrically connecting the battery pack to the hand held power tool; and
a circuit configured to control a discharge of the plurality of battery cells to produce a discharge current from the plurality of battery cells, an average of the discharge current produced by the plurality of battery cells being greater than or equal to approximately 20 amps.
US Pat. No. 10,214,608

SURFACE MODIFICATION METHOD AND SURFACE-MODIFIED BODY

SUMITOMO RUBBER INDUSTRIE...

1. A method for suppressing adsorption of proteins or cells to an object made of a rubber vulcanizate or a thermoplastic resin, the method comprising:a step 1 of forming polymerization initiation points on a surface of the object; and
a step 2 of radically polymerizing a hydrophilic monomer starting from the polymerization initiation points by irradiation with UV light having a wavelength of 300 to 400 nm for 3 minutes or more in the presence of an alkali metal salt so as to grow polymer chains on the surface of the object,
wherein the alkali metal salt is at least one selected from the group consisting of halogenated alkali metal salts, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydrogen carbonates, alkali metal nitrates, alkali metal sulfates, alkali metal bisulfates, alkali metal phosphates, alkali metal hydroxides, alkali metal acetates, alkali metal citrates, and alkali metal lactates; and
wherein the alkali metal salt is a water-soluble lithium, sodium, potassium, rubidium or cesium salt.
US Pat. No. 10,214,609

POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF

THE UNIVERSITY OF WESTERN...

1. A capped polymer comprising a polyglyoxylate polymer having a polyacetal backbone with pendant esters and a terminal hydroxyl, an end capping molecule separate from the polymer that is a protecting group for the polyglyoxylate's terminal hydroxyl or a self-immolative spacer covalently linked to the protecting group, which is linked to an end thereof by a covalent linkage, wherein the end capping molecule is able to undergo selective cleavage from the polyglyoxylate polymer upon exposure to a preselected stimulus, wherein said selective cleavage is cleavage only of said covalent linkage of the end capping molecule to the end of the polymer thus leaving the polyacetal backbone and the pendant esters intact to produce the polyglyoxylate polymer without the end capping molecule.
US Pat. No. 10,214,612

EPOXY RESIN COMPOSITION COMPRISING 2-(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)PROPANE-1,3-DIAMINE AS HARDENER

Evonik Degussa GmbH, Ess...

1. An epoxy resin composition comprising:A) an epoxy compound
and
B) a hardener composition comprising:
B1) from 0.1%-100% by weight of 2-(2,2,6,6-tetramethylpiperidin-4-yl)propane-1,3-diamine
and
B2) from 99.9%-0% by weight of at least one further diamine and/or polyamine,
where the stoichiometric ratio of the epoxy groups of A) and the number of active hydrogen atoms of the functional groups of B) varies from 1:2 to 2:1,
C) optionally from 0.1% to 10% by weight of at least one hardening accelerator,
D) optionally at least one latent hardener,
where the amounts of A)-D) add up to 100% by weight,
E) optionally further additives.
US Pat. No. 10,214,613

POLYESTER RESINS BASED ON FATTY ACIDS THAT HAVE A SHORT OIL LENGTH, AQUEOUS DISPERSIONS AND ASSOCIATED COATINGS

Arkema France, Colombes ...

1. A polyester alkyd resin,derived from at least one fatty acid and an alcohol component comprising at least one polyol of functionality ranging from 2 to 10, and
an acid component comprising, in addition to said fatty acid, from 45% to 75% by weight, relative to the total weight of said resin, of rosin and/or rosin derivatives bearing at least one carboxylic acid function,
said resin having a zero oil content (0%) and said fatty acid being selected from the group consisting of non-oxidizable fatty acids with a corresponding content of oxidizable unsaturations that is 0 mmol per g of dry resin or said resin having an oil content up to 5% and wherein in addition to said fatty acid selected from the group consisting of non-oxidizable fatty acids, further comprising in minor weight proportions the oxidizable fatty acid leading to said oil content ranging up to 5%, and having a weight ratio of oxidizable fatty monoacids relative to the overall fatty acids of 0 or higher than 0 and corresponding to said oil content up to 5%,
said resin having an acid number less than 8 and a number-average molecular mass Mn, measured by GPC as polystyrene equivalents in THF, ranging from 1,000 to 10,000,
wherein said non-oxidizable fatty acid is selected from the group consisting of fatty acid oligomers.
US Pat. No. 10,214,615

POLYIMIDE COMPOSITION

Croda International Plc, ...

1. Polyimide formed from at least one dianhydride and at least one dimer fatty diamine and at least one aromatic diamine,wherein at least 50 wt. % of the total amount of diamine is comprised of dimer fatty diamine, and
wherein at least one aromatic diamine is present in an amount of at least 5 wt. % of the total diamine,
wherein the dimer fatty diamine has a trimer fatty triamine content of less than 1 wt. %,
wherein the polyimide has a weight average molecular weight in the range 10,000 to 300,000, and
wherein the at least one aromatic diamine is selected from the group consisting of 4,4?-diaminodiphenyl ether, 3,4?-diaminodiphenyl ether, 3,3?-diaminodiphenyl ether, o-tolidine, m-tolidine, 4,4?-diaminobenzanilide, p-phenylenediamine, and m-phenylenediamine.
US Pat. No. 10,214,616

ANAEROBICALLY STORED BIOMASS HAVING HIGHLY REDUCED OR NO FERMENTATION

1. An anaerobically stored wet biomass mash obtained by a method comprising:providing a composition comprising a biomass, wherein the biomass comprises a Neutral Detergent Fiber (NDF) value of less than 45% of dry matter content and lignin in an amount of less than 10% of the dry matter content, and wherein the biomass is selected from the group consisting of alfalfa, corn, grass, clover, beet crop, sugar cane, pea, bean, whole crop cereal, sorghum, sunflower, and mixtures thereof;
subjecting the composition to a pH adjusting step under anaerobic conditions, in which the pH is adjusted with a base to a pH of 7.5 or more at a temperature of 1 to 40° C. for a period of at least 2 days, thereby generating a pH adjusted wet biomass mash for anaerobic storage.
US Pat. No. 10,217,947

ORGANIC COMPOUND AND ELECTRONIC DEVICE USING SAME

NICHEM FINE TECHNOLOGY CO...

1. An organic compound comprising:a electron donating 4,4?-substituted cis-stilbene segment;
a bridge atom segment having a bridge atom with four bonds, and the bridge atom is connected to the electron donating 4,4?-substituted cis-stilbene segment with two of the four bonds to form a 7-membered ring structure; and
an imidazole segment connected to the electron donating 4,4?-substituted cis-stilbene segment.
US Pat. No. 10,215,897

INFRARED LIGHT ABSORBING AMINIUM AND DIIMMONIUM COMPOSITIONS

NOTICXE, INC., Dayton, O...

1. An infrared light absorbing aminium composition comprising:an aminium radical cation that has at least one absorption peak in the near infrared wavelength region between about 700 and 1500 nm and having the formula:
[4-R1R2N—C6H3CH3][4-R3R4N—C6H3CH3][4-R5R6N—C6H3CH3]N+where R1 through R6 are identical or different, optionally are linked to form rings, and are each an alkyl group, an arylalkyl group, an alkyl ether, or hydroxyalkyl group, andan anionic borate moiety having the formula:
[BXaYb]?in which a and b are integers, and a ranges from 0 to 3, b ranges from 1 to 4, and a+b=4; each X is a halogen atom, which is identical or different or an OH functional group, and each Y, which is identical or different, is a phenyl radical, which is substituted by at least one element or electron-withdrawing substituent or by one or more halogen atoms, or an aryl radical containing at least two aromatic ring members, which is optionally substituted.
US Pat. No. 10,214,618

LOW DENSITY CORING MATERIAL

Illinois Tool Works Inc.,...

1. A process for making a composition for a low density coring material comprising:providing one or more resins, a monomer, and a dispersion aid;
performing a first mixing of the one or more resins, the monomer, and the dispersion aid with a mixer to form a resin mixture;
adding one or more accelerators into the resin mixture;
performing a second mixing of the added one or more accelerators and the resin mixture;
adding microspheres to the mixture of the one or more accelerators and the resin mixture while performing a third mixing; and
performing a fourth mixing and filtering the composition through a mesh to yield the low density coring material, the coring material having a cured state and an uncured state, the viscosity of the coring material in the uncured state is in a range of from 7,000 to 13,000 cps, wherein a density of the cured coring material is less than about 5.0 lbs/gal, a layer of low density coring material having a wet thickness from 15 to 40 mils per pass.
US Pat. No. 10,214,620

NANO-REINFORCEMENT FILLER MATERIAL FOR EPOXY RESIN SYSTEMS AND METHODS OF MAKING THE SAME

The Boeing Company, Chic...

1. A method of making a nano-reinforcement filler material for an epoxy resin system for a composite structure, the method comprising the steps of:forming a polymer suspension comprising a plurality of polymer nanoparticles suspended in deionized (DI) water;
sonicating the polymer suspension to obtain a sonicated polymer suspension; forming a graphene oxide (GO) suspension comprising a plurality of graphene oxide (GO) sheets suspended in deionized (DI) water;
sonicating the graphene oxide (GO) suspension to obtain a sonicated graphene oxide (GO) suspension;
mixing the sonicated polymer suspension and the sonicated graphene oxide (GO) suspension together in a mixing vessel, to obtain a sonicated mixture; and
heating the sonicated mixture in an inert atmosphere at an effective temperature in a range of from 7020 C. (seventy degrees Celsius) to about 100° C. (one hundred degrees Celsius), and using an electrostatic process to uniformly wrap individual polymer nanoparticles with individual graphene oxide (GO) sheets, via an electrostatic interaction reaction, to obtain the nano-reinforcement filler material comprising polymer-GO core-shell nanoparticles.
US Pat. No. 10,214,621

BINARY PROCESS FOR MANUFACTURE OF DIPPED LATEX PRODUCTS

TTK Healthcare Limited, ...

1. A binary process for manufacturing dipped latex product, the said process comprising:preparing a first latex mixture Formulation A comprising latex, one or more accelerators, and one or more surfactants but no curing agents;
preparing a second latex mixture Formulation B comprising latex, one or more curing agents, and one or more surfactants but no curing accelerators;
dipping one or more formers into the Formulations A and B separately in order to form a plurality of coatings/layers of the Formulations A and B; and
curing the plurality of coatings/layers on the formers to form the dipped latex products.
US Pat. No. 10,214,625

POLYOLEFIN NANOCOMOSITES MATERIALS

Basell Poliolefine Italia...

1. A process for the preparation of a polyolefin nanocomposite material comprising:melt mixing
(i) a crystalline or semi-crystalline polyolefin resin component (A),
(ii) a nanosized mineral filler comprising or substantially consisting of a hydrotalcite (B), and
(iii) a compatibilizer,
wherein the amount of the hydrotalcite is from 0.02 to 6 parts by weight per 100 parts by weight of the nanocomposite material, and the ratio MFR (1)/MFR (2) of the melt flow rate value MFR (1) of component (A) to the melt flow rate value MFR (2) of the polyolefin nanocomposite material is of at least 1.02, and
wherein the melt mixing is at a shear mixing rate ranging from 30 to 300 sec?1.
US Pat. No. 10,214,628

PLASTICIZER BLENDS AND PLASTISOL COMPOSITIONS COMPRISED THEREOF

Emerald Kalama Chemical, ...

1. A plastisol composition comprising:a) a polymer;
b) an organic solvent as a diluent to reduce viscosity wherein the organic solvent is a mineral spirit, cycloaliphatic or other petroleum distillate, detergent alkylate or isoparaffin; and,
c) a plasticizer blend comprising a dibenzoate plasticizer as the primary plasticizer mixed in combination with a compatibilizing component consisting of dioctyl succinate, 1,2-propylene glycol dibenzoate or 3-phenyl propyl benzoate, present in the plastisol in an amount of about 30 to about 120 phr total plasticizer content,
wherein 1,2-propylene glycol dibenzoate is not used as a compatibilizing component when it comprises a part of the primary plasticizer.
US Pat. No. 10,214,630

NATURAL CRYSTALLINE COLORANT AND PROCESS FOR PRODUCTION

1. A process, comprising:purifying algae containing pigments by removing at least a portion of non-pigment compounds from the algae to recover a purified pigment;
drying the purified pigment by refractive window drying to produce a crystalline product and milling the crystalline product.
US Pat. No. 10,214,632

CRYSTALLINITY MODIFIER FOR POLYOLEFINS

INDIAN OIL CORPORATION LI...

1. A process for modification of acid scavenger to be used as dual functional additive as acid scavenger as well as crystallinity modifier in polyolefins, said process comprising:treating an acid scavenger with an organic dibasic acid at a temperature in the range of 140° C. to 160° C. without any solvent in a dry method to obtain a modified acid scavenger, wherein the acid scavenger is calcium aluminium hydroxy carbonate having chemical formula Ca4Al2(OH)12CO3.nH2O, where n=4-5.
US Pat. No. 10,213,865

METHOD FOR WELDING A CASE HARDENED COMPONENT

Whirlpool Corporation, B...

1. A method for producing a welded part comprising a first component welded to a second component, the method comprising:case hardening the surface of the first component by a salt bath nitriding process; and
after case hardening the surface of the first component, welding the case hardened first component to the second component by a gas metal arc welding process using an aluminum-bronze wire electrode.
US Pat. No. 10,214,635

SULFUR-CROSSLINKABLE RUBBER MIXTURE AND VEHICLE TIRE

Continental Reifen Deutsc...

1. A sulfur-crosslinkable rubber mixture comprising:at least one diene rubber;
10 to 200 phr of at least one silica; and,
2 to 20 phf of at least one silane having the general empirical formula:
[(R1)3Si—X]mSn(R2)2-m wherein the R1 radicals may be the same or different within one molecule, wherein the R1 radicals selected from the group consisting of alkoxy groups having 1 to 10 carbon atoms, cyclic dialkoxy groups having 2 to 10 carbon atoms, cycloalkoxy groups having 4 to 10 carbon atoms or phenoxy groups, aryl groups having 6 to 20 carbon atoms, alkyl groups having 1 to 10 carbon atoms, alkenyl groups having 2 to 20 carbon atoms, aralkyl groups having 7 to 20 carbon atoms, and halides, wherein X is a polar organic urea-containing group, wherein m assumes the value of 1 or 2, wherein n is an integer from 1 to 8, and wherein R2 is a hydrogen atom or an acyl group having 1 to 20 carbon atoms; and,wherein the polar organic urea-containing X group comprises at least one urea derivative as polar functionality which bears an organic hydrocarbyl group on the two nitrogen atoms, wherein the group between the first nitrogen atom of the urea-containing group and the sulfur of the Sn group is aliphatic, and wherein the group between the second nitrogen atom of the urea-containing group and the silicon atom of the (R1)3Si group is aliphatic or aromatic.
US Pat. No. 10,214,636

RUBBER COMPOSITION FOR A TIRE TREAD

KUMHO TIRE CO., INC., Gw...

1. A rubber composition for a tire tread, comprising:6 to 20 parts by weight of a silane coupling agent having a thioester group and SiO bond; and
1 to 20 parts by weight of terpene resin having a softening point of 130° C. or more and a weight average molecular weight of 1,000 or more, to 100 parts by weight of raw rubber,
wherein the raw rubber comprises:
10 to 30% by weight of end modified styrene-butadiene rubber, in which a styrene unit content is 20% by weight or less and a vinyl unit content is 30% by weight or less,
30% to 50% by weight of styrene-butadiene rubber, and
20% to 60% by weight of butadiene rubber or natural rubber.
US Pat. No. 10,214,638

RUBBER COMPOSITION COMPRISING AN AROMATIC DICYCLOPENTADIENE RESIN

Compagnie Generale Des Et...

1. A rubber composition based on at least one styrene/butadiene copolymer SBR, the SBR having a content of greater than or equal to 50 parts per hundred parts of elastomer, phr, a reinforcing filler comprising carbon black with a CTAB specific surface area of greater than or equal to 90 m2/g, wherein the composition comprises an aromatic dicyclopentadiene plasticizing resin comprising at least 80% by weight of units selected from each of styrene, ethylene and dicyclopentadiene units, at a content ranging from 2 to 40 phr, the composition containing less than 5 phr of another plasticizer.
US Pat. No. 10,214,639

POST CONSUMER RECYCLED RESIN COMPOSITION AND MANUFACTURE OF TUBES THEREFROM

Essel Propack Ltd., Mumb...

1. A laminate comprising: an outer layer of a post-consumer recycled polymer composition consisting of 80% to 95% (w/w) of a post-consumer recycled resin, and 5% to 20% (w/w) of ethylene alpha olefin co-polymer; a middle layer of post-consumer recycled polymer composition consisting of 80% to 95% (w/w) of a post-consumer recycled resin, and 5% to 20% (w/w) of ethylene alpha olefin co-polymer; an inner layer comprising a virgin polyethylene resins, and wherein the post-consumer recycled resin is a High Density Polyethylene (HDPE) resin.
US Pat. No. 10,214,640

SOFT AND FLEXIBLE POLYOLEFIN COMPOSITION

Basell Poliolefine Italia...

1. A polyolefin composition comprising:A) from about 63 to about 78% by weight, based upon the total weight of the polyolefin composition, of a copolymer of butene-1 with ethylene having a copolymerized ethylene content of up to about 18% by mole, based upon the molar composition of the copolymer, and no melting peak detectable at the DSC at the second heating scan and
B) from about 22 to about 37% by weight, based upon the total weight of the polyolefin composition, of (i) a propylene homopolymer, or (ii) a propylene copolymer, or (iii) a mixture of two or more of (i) and (ii), having a melting temperature Tm, measured by DSC at the second heating scan, of from about 130° C. to about 165° C.,wherein (i) the amounts of A) and B)=100 and referred to as the total weight of A)+B) and the DSC second heating scan is carried out with a heating rate of 10° C. per minute and (ii) having a melting enthalpy ?Hfus, measured by DSC at the second heating scan of from about 7 to about 30 J/g.
US Pat. No. 10,214,641

AQUEOUS ORGANIC SILICON FLUORO-CONTAINING POLYMER DISPERSION AND METHOD FOR MANUFACTURING THE SAME

GRAND TEK ADVANCE MATERIA...

1. An aqueous organic silicon fluoro-containing polymer dispersion, comprising:100 parts by weight of a poly(vinylidene difluoride-hexafluoropropylene);
10 to 30 parts by weight of an organic silicon emulsion; and
an acrylate polymer, wherein the acrylate polymer and the sum of the poly(vinylidene difluoride-hexafluoropropylene) and the organic silicon emulsion have a weight ratio of 30:100 to 50:100.
US Pat. No. 10,214,642

THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE MANUFACTURED THEREFROM

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin composition, comprising:7 to 50% by weight of an acrylic rubber-aromatic vinyl compound-vinyl cyan compound graft copolymer (a);
7 to 40% by weight of a silicone-acrylate based copolymer (b);
5 to 20% by weight of a (meth)acrylic acid alkyl ester compound-aromatic vinyl compound-vinyl cyan compound copolymer (c);
30 to 75% by weight of a total (d) of a highly heat-resistant (meth)acrylic acid alkyl ester polymer (d-1) having a heat resistance of greater than 91° C. and a flow index (230° C., 3.8 kg) of 1 g/10 min to 5 g/10 min and a high-fluidity (meth)acrylic acid alkyl ester polymer (d-2) having a heat resistance of 91° C. or less and a flow index of greater than 5 g/10 minutes; and
0 to 5% by weight of a (meth)acrylic acid alkyl ester compound-aromatic vinyl compound-acid anhydride copolymer (e).
US Pat. No. 10,214,643

RECYCLED POLYETHYLENE TEREPHTHALATE COMPOSITIONS, FIBERS AND ARTICLES PRODUCED THEREFROM, AND METHODS FOR PRODUCING SAME

Columbia Insurance Compan...

1. An extruded polymer composition consisting essentially of polyethylene terephthalate polymer composition, wherein the polyethylene terephthalate polymer composition has about 25% by weight to about 100% by weight of homogenized deposit post-consumer polyethylene terephthalate and balance virgin polyethylene terephthalate, and wherein the homogenized deposit post-consumer polyethylene terephthalate comprises at least one impurity not present in virgin polyethylene terephthalate.
US Pat. No. 10,214,644

DARK POLYCARBONATE COMPOSITION

SABIC GLOBAL TECHNOLOGIES...

1. A flame-retardant polycarbonate blend, comprising:from about 30 wt % to about 80 wt % of a blend of a high molecular weight polycarbonate polymer having a Mw above 25,000 and a low molecular weight polycarbonate polymer having a Mw below 25,000 which when blended together have an average molecular weight from about 25,000 to about 30,000:
a polycarbonate-polysiloxane copolymer in an amount such that the blend contains from about 2 wt % to about 5 wt % of siloxane, wherein the polycarbonate-polysiloxane copolymer is different from the high molecular weight polycarbonate polymer and the low molecular weight polycarbonate polymer;
from about 0.01 wt % to about 0.05 wt % of a non-brominated and non-chlorinated flame retardant;
from about 1 wt % to about 10 wt % of titanium dioxide (TiO2); and
from about 0.2 wt % to about 2 wt % of carbon black;
wherein the ratio of TiO2 to carbon black is from about 4:1 to about 6:1; and wherein the blend has an L-value of 20 or less; meets CTI PLC 2 standards when measured according to ASTM D3638; has V0 performance at 0.08 mm thickness; and has 100% ductility at ?30° C.
US Pat. No. 10,213,879

SOLDER ALLOY

SENJU METAL INDUSTRY CO.,...

1. A solder alloy for forming a fillet, the solder alloy having an alloy composition consisting of, in mass %:Bi: 0.3 to 0.8%;
Ag: 0 to less than 0.2%; and
P: 0.001 to 0.1%,
with the balance being Sn, and
a total amount of Ag and Bi being from 0.3 to 0.8%, whereby deterioration of the alloy by thermal fatigue and fillet abnormality is suppressed.
US Pat. No. 10,213,368

ORAL CARE COMPOSITIONS

1. An oral care composition comprising:a. from 0.01% to 2% by weight of a stannous chloride source;
b. a thickening agent consisting of:
i) from 1% to 5% by weight carrageenan; and
ii) from 0.3% to 0.875% by weight xanthan gum;
c. at least 30% by weight of a total water content; and
d. from 20% to 80% of a humectant selected from the group consisting of glycerin, sorbitol, xylitol, butylene glycol, polyethylene glycol, propylene glycol, and combinations thereof;
e. a dental abrasive consisting of precipitated silica;
f. from 0.01% to 2% by weight of a fluoride ion source;
wherein the composition has a pH of greater than 4 and comprises less than 0.001% of a charged cellulose derivative having greater than 0.5 charged groups per sugar residue unit along the polysaccharide backbone;
wherein the composition has a Tip Viscosity of greater than 100 Pa·s after 4.5 months at 40° C.;
wherein the xanthan gum has a degree of substitution of less than 0.4 carboxylate groups per sugar residue.
US Pat. No. 10,213,880

SOLDER ALLOY, SOLDER PASTE, AND ELECTRONIC CIRCUIT BOARD

HARIMA CHEMICALS, INCORPO...

1. A solder alloy consisting essentially of:tin, silver, copper, bismuth, antimony, indium, and nickel, wherein
with respect to the total amount of the solder alloy,
the content ratio of the silver is 0.05 mass % or more and below 0.2 mass %;
the content ratio of the copper is 0.7 mass % or more and 1 mass % or less;
the content ratio of the bismuth is above 4.0 mass % and 10 mass % or less;
the content ratio of the antimony is 0.005 mass % or more and 8 mass % or less;
the content ratio of the indium is 0.005 mass % or more and 2 mass % or less;
the content ratio of the nickel is 0.003 mass % or more and 0.4 mass % or less; and
the content ratio of the tin is the remaining ratio and
the mass ratio (Bi/Ni) of the bismuth content with respect to the nickel content is 35 or more and 1500 or less.
US Pat. No. 10,215,672

BIOCOMPATIBLE METHOD OF FUNCTIONALISING SUBSTRATES WITH INERT SURFACES

KODE BIOTECH LIMITED, Au...

1. A method of localizing a functional moiety to the surface of a glass membrane by non-covalent interactions comprising the steps of:immersing the glass membrane in an aqueous dispersion of a construct of the structure F-S-L; and then
washing the glass membrane with an aqueous vehicle to provide the functionalised surface,
wherein F is the functional moiety, S is a spacer selected to provide a construct that is dispersible in water, and L is a diacyl- or dialkyl-glycerophospholipid.
US Pat. No. 10,213,369

ORAL COMPOSITIONS CONTAINING METAL IONS

Colgate-Palmolive Company...

1. An oral care composition comprising:(a) a stannous ion source;
(b) a zinc ion source;
(c) polyphosphate; and
(d) a thickening agent comprising:
(i) 1 to 3.5 weight % of polyvinylpyrrolidone,
(ii) 0.2 to 0.45 weight % of a polysaccharide gum, and
(iii) 0.05 to 0.3 weight % of carboxymethyl cellulose
wherein the weight % is by weight of the composition.
US Pat. No. 10,213,370

DENTIFRICE COMPOSITIONS WITH IMPROVED FLUORIDE STABILITY

1. A dentifrice composition comprising:(a) 45% to 75%, by weight of the composition, of water;
(b) 25% to 50%, by weight of the composition, of a calcium-containing abrasive;
(c) 0.0025% to 2%, by weight of the composition, of a fluoride ion source;
(d) greater than 0.3%, by weight of the composition, of alkaline metal carbonate;
(e) from 0.001% to 3%, by weight of the composition, of an alkali metal phosphate; and
(f) a pH greater than 9.
US Pat. No. 10,214,650

AQUEOUS COMPOSITE PARTICLE DISPERSION

ASAHI KASEI KABUSHIKI KAI...

1. An aqueous dispersion of composite particles comprising:an aqueous medium including water; and
composite particles dispersed in the aqueous medium,
wherein
the composite particles has a particle (A), and a polymer layer (B) encapsulating at least a part of a surface of the particle (A);
the particle (A) is at least any one particle of an inorganic solid particle, or a silica-encapsulated particle having a core particle and a silica layer encapsulating at least a part of a surface of the core particle; and
a zeta potential of the composite particles in the aqueous dispersion of composite particles at 60° C. is ?70 mV to ?160 mV at any pH in the range from 7 to 11.
US Pat. No. 10,213,627

ORAL COMPOSITIONS AND USES THEROF

Colgate-Palmolive Company...

1. An oral composition comprising an orally-acceptable carrier and an abrasive system consisting essentially of a precipitated silica abrasive, whereinthe precipitated silica abrasive has an average particle size of from 9 ?m to 13 ?m; and
an Einlehner hardness of from 6 to 9;
wherein the mean particle size of the precipitated silica abrasive is reduced by 16% to 20% after being applied to a hard surface in an oral cavity for from 30 seconds to 5 minutes;
wherein the precipitated silica abrasive is present in an amount from 10% to 20% weight of the composition;
wherein the precipitated silica abrasive has an oil absorption from 80 cc/100 g to 100 cc/100 g;
wherein the composition has a pellicle cleaning ratio of from 80 to 105 and has a radioactive dentin abrasion of less than 150;
wherein a 10% aqueous slurry consisting of the precipitated silica abrasive has a PCR/RDA ratio of from 0.7 to 0.9; and
wherein the only silica in the oral composition is the precipitated silica.
US Pat. No. 10,217,982

METHOD FOR PRODUCING LAMINATED POROUS FILM

SUMITOMO CHEMICAL COMPANY...

1. A method for producing a laminated porous film comprising a treated porous film and a heat-resistant layer,the method comprising treating an untreated porous film to provide the treated porous film, and
forming a heat-resistant layer comprising a filler on the surface of the treated porous film by applying a coating slurry comprising a solvent, a binder resin and the filler to the surface of the treated porous film and then removing the solvent,
wherein the coating slurry is prepared so as to have a contact angle of 75° or more with the untreated porous film to prevent the coating slurry from penetrating into the treated porous film, and the viscosity of the coating slurry is in the range of not less than 300 cP and not more than 10000 cP.
US Pat. No. 10,213,372

METHOD FOR SIMULTANEOUSLY AND PERMANENTLY RESHAPING AND COLORING KERATIN FIBERS

1. A method for permanently reshaping and changing the color of keratinic fibers, in a single process, with the method comprising the following method steps in the indicated sequence:a) styling of keratinic fibers using styling aids,
b) application of an aqueous composition (M1) including at least one keratin-reducing compound selected from the group consisting of thioglycolic acid, thiolactic acid, cysteine, and salts thereof and present in a total quantity of 10 to 15 wt % based on the total weight of the aqueous composition (M1), at least one alkalizing agent that is ammonium hydrogen carbonate and/or ammonium hydroxide, and present in a total quantity of 1.5 to 7 wt % based on the total weight of the aqueous composition (M1), and at least one surfactant selected from the group consisting of alkyl (ether) sulfates, alkyl betaines, alkyl polyglucosides, and nonionic surfactants, and present in a total quantity of 3.0 to 7.0 wt % based on the total weight of the aqueous composition (M1), from an applicator as a foam onto the keratinic fibers located on the styling aids and leaving this aqueous composition (M1) on the keratinic fibers located on the styling aids for a period of 5 to 50 minutes,
c) rinsing and, optionally, drying of the keratinic fibers located on the styling aids,
d) application of an aqueous foam composition (M2) including at least one oxidation dye precursor present in an amount of from 0.5 to 3 wt % with respect to the total weight of the aqueous foam composition (M2), at least one oxidizing agent that is hydrogen peroxide and is present in a total quantity of 1.5 to 7.5 wt % based on the total weight of the aqueous foam composition (M2), at least one alkalizing agent that is monoethanolamine and that is present in an amount of from 2.0 to 6.0 wt % with respect to the total weight of the aqueous foam composition (M2), and at least one surfactant from an applicator onto the keratinic fibers located on the styling aids and leaving this aqueous foam composition (M2) on the keratinic fibers located on the styling aids for a period of 10 to 15 minutes,
e) removal of the styling aids from the keratinic fibers,
f) distribution of the aqueous foam composition (M2) applied in step (d) remaining on the keratinic fibers and/or repeated application of the aqueous foam composition (M2) and leaving this aqueous foam composition (M2) on the keratinic fibers for a period of 15 to 30 minutes,
g) rinsing of the keratinic fibers, and
h) optionally, application of a post-treatment agent to the keratinic fibers
wherein the aqueous foam composition (M2) used in step (d) includes, as a surfactant, at least one alkyl betaine, at least one alkyl polyglucoside, at least one nonionic surfactant having an HLB value of greater than 10, and at least one anionic surfactant,
wherein the aqueous foam composition (M2) used in method step (d) includes the at least one surfactant in total quantity of 20 to 27 wt % with respect to the total weight of the aqueous foam composition (M2), and
wherein each foam of step (b) and (d) is independently a colloid-chemical system composed of gas-filled cells that are bordered by a fluid, semifluid, or highly viscous cell web.
US Pat. No. 10,214,652

ALUMINUM-COPPER COMPOSITE SEMI-FINISHED PRODUCT FOR ELECTRICAL ENGINEERING AND METHOD FOR PRODUCING SAME

DODUCO SOLUTIONS GMBH, P...

1. A method for producing a semi-finished product for electrical engineering comprising the following steps:producing a composite from an aluminium sheet and a copper sheet, wherein the aluminium sheet and the copper sheet are joined by rolling;
applying an acrylate-based lacquer to the composite, the acrylate-based lacquer containing acrylate monomers and at least one photoinitiator; and
polymerizing the acrylate monomers with radiation.
US Pat. No. 10,217,983

CROSS-LINKED COMPOUND PARTICLE AND SECONDARY BATTERY INCLUDING THE SAME

LG Chem, Ltd., (KR)

1. A compound particle comprised in an electrolyte for a lithium-ion polymer battery, wherein the compound particle comprises:a monomer and a polymerization initiator, as a core; and
a film as a shell,
wherein the monomer is acrylonitrile,
wherein the film comprises a thermoplastic resin that is polyacrylonitrile (PAN), and
wherein the polymerization initiator is a photoinitiator, a thermoinitiator, a radiation initiator or a mixture thereof.
US Pat. No. 10,213,373

CHROMOPHORE COMBINATIONS FOR BIOPHOTONIC USES

KLOX TECHNOLOGIES, INC., ...

1. A biophotonic composition for topical application to a target tissue, the biophotonic composition comprising a first xanthene dye and at least one other xanthene dye, wherein the first xanthene dye is Eosin Y and is present in the biophotonic composition at a concentration of between about 0.5 mg/mL and about 1 mg/mL; and wherein the at least one other xanthene dye is present in the biophotonic composition at a concentration of between about 0.001% and about 0.5% per weight of the biophotonic composition.
US Pat. No. 10,213,374

ORAL CARE COMPOSITIONS AND METHODS OF USE

Colgate-Palmolive Company...

1. A naringin:Zn complex, wherein said naringin:Zn complex has a 2:1 naringin to zinc molar ratio.
US Pat. No. 10,214,654

METHOD FOR FORMING MULTILAYER COATING FILM

NIPPON PAINT AUTOMOTIVE C...

1. A method for forming a multilayer coating film comprising the steps of:(1) applying a first water-based base coating composition on a surface of a coating material to form an uncured first water-based base coating film,
(2) applying a second water-based base coating composition on the uncured first water-based base coating film to form an uncured second water-based base coating film,
(3) applying a clear coating composition on the uncured second water-based base coating film to form an uncured clear coating film, and
(4) simultaneously heating and curing the uncured first water-based base coating film, the uncured second water-based base coating film and the uncured clear coating film formed in the steps (1), (2) and (3) to form a multilayer coating film, wherein:
the first water-based base coating composition comprises an acrylic emulsion resin, a curing agent and a hydrophilic associated type viscosity agent, wherein the curing agent is a melamine resin, and the hydrophilic associated type viscosity agent is a polyamide type viscosity agent; and
the second water-based base coating composition comprises a film forming resin, and the film forming resin comprises:
an acrylic emulsion resin (A) comprising a single layered acrylic emulsion resin (a) and a core-shell type acrylic emulsion resin (b) and each of (a) and (b) obtained by emulsion polymerization of a monomer mixture containing a (meth)acrylic acid alkyl ester (i), an ethylenically unsaturated monomer having an acid group (ii) and an ethylenically unsaturated monomer having a hydroxyl group (iii),
a water soluble acrylic resin (B) prepared by co-polymerization of a hydroxyl group-containing monomer and another monomer,
wherein the another monomer is at least one selected from the group consisting of a carboxyl group-containing monomer, a dicarboxylic acid monoester monomer, a (meth)acrylate alkylester monomer, an alicyclic group-containing monomer, a (meth)acrylic acid aminoalkyl ester monomer, a (meth)acrylic acid aminoalkyl amide monomer, an amido group-containing monomer, a vinyl cyanide monomer, a saturated aliphatic carboxylic acid vinyl ester monomer and a styrene monomer, and
a water soluble polyester resin (C) prepared by polycondensation reaction of a polyalcohol with a polybasic acid or anhydride thereof,
wherein the polyalcohol is at least one selected from the group consisting of ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, neopentylglycol, 1,2-butanediol, 1,3-butanediol, 2,3-butanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, hydrogenated bisphenol A, hydroxyalkylated bisphenol A, 1,4-cyclohexanedimethanol, 2,2-dimethyl-3-hydroxypropyl-2,2-dimethyl-3-hydroxypropionate, 2,2,4-trimethyl-1,3-pentanediol, N,N-bis-(2-hydroxyethyl) dimethyl hydantoin, polytetramethylene ether glycol, polycaprolactone polyol, glycerin, sorbitol, trimethylol ethane, trimethylol propane, trimethylol butane, hexanetriol, pentaerythritol, dipentaerythritol and tris-(hydroxyethyl) isocyanate, and
wherein the polybasic acid or anhydride thereof is at least one selected from the group consisting of phthalic acid, phthalic anhydrite, tetrahydrophthalic acid, tetrahydrophthalic anhydrite, hexahydrophthalic acid, hexahydrophthalic anhydrite, methyl tetrahydrophthalic acid, methyl tetrahydrophthalic anhydrite, himic anhydride, trimellitic acid, trimellitic anhydride, pyromellitic acid, pyromellitic anhydride, isophthalic acid, terephthalic acid, maleic acid, maleic anhydride, fumaric acid, itaconic acid, adipic acid, azelaic acid, sebacic acid, succinic acid, succinic anhydride, lactic acid, dodecenyl succinic acid, dodecenyl succinic anhydride, cyclohexane-1,4-dicarboxylic acid and endo anhydride; andwherein,a rate represented by the following formula:
(A)/(A+B+C)
wherein (A) is a resin solid content by mass of the acrylic emulsion resin (A), and (A+B+C) is a total resin solid content by mass of the acrylic emulsion resin (A), the water soluble acrylic resin (B) and the water soluble polyester resin (C),is from 40% to 60% expressed in percentage.
US Pat. No. 10,213,119

SYSTEMS AND METHODS FOR DETERMINATION OF BLOOD FLOW CHARACTERISTICS AND PATHOLOGIES THROUGH MODELING OF MYOCARDIAL BLOOD SUPPLY

HeartFlow, Inc., Redwood...

1. A computer-implemented method of building a patient-specific anatomic model, the method comprising:receiving a vascular model associated with one or more individuals;
receiving a tissue model associated with the one or more individuals;
calculating a first perfusion value using the vascular model and the tissue model;
determining, using a fluid dynamics computation, a first vascular pathology of the vascular model used for the calculation of the first perfusion value;
receiving, for a given patient, a patient-specific observed perfusion value;
deforming a stored vascular model based on the first vascular pathology and the received patient-specific observed perfusion value;
calculating a second perfusion value using the deformed vascular model; and
generating a patient-specific vascular model based on a comparison of for which the second perfusion value matches the patient-specific observed perfusion value and the deformed vascular model.
US Pat. No. 10,213,375

COSMETIC OR DERMATOLOGICAL COMPOSITIONS COMBINING COSMETIQUES RETINALDEHYDE AND GLYCYLGLYCINE OLEAMIDE AND THE COSMETIC OR DERMATOLOGICAL USES THEREOF

PIERRE FABRE DERMO-COSMET...

1. A method for combating ageing of the skin by increasing the physiological stores of vitamin A in the skin, said method comprising:applying on the skin a therapeutically effective amount of a cosmetic or dermatological composition comprising as an active ingredient retinaldehyde and glycylglycine oleamide and at least one cosmetically or dermatologically acceptable carrier.
US Pat. No. 10,213,376

METHOD OF SUPPRESSING COLORATION OF CATECHINS AND A DENTIFRICE COMPOSITION

KAO CORPORATION, Tokyo (...

1. A dentifrice composition comprising hydrogel particles (A), a binder (B) and water (C), wherein:the hydrogel particles (A) comprise catechins (A1), a water-soluble polymer (A2) capable of forming a water-insoluble complex with catechins, a gel former (A3) and water (A4);
the polymer (A2) is selected from polyvinyl pyrrolidone, polyvinyl alcohol and hydroxyethyl cellulose;
the gel former (A3) is at least one selected from agar, ?-carrageenan, ?-carrageenan, ?carrageenan, furcelleran, alginate, propylene glycol alginate, guar gum, locust bean gum, tamarind seed polysaccharides, tara gum, quassia gum, pectin, arabinogalactan, xanthan gum, scleroglucan, pullulan, dextran, gellan gum, curdlan, gelatin, albumin, casein, soy protein, wheat protein, carboxymethyl cellulose, methyl cellulose, microcrystalline cellulose, starch, starch phosphate and starch glycolate;
the hydrogel particles (A) have an average particle size of 5 to 5000 ?m;
the binder (B) is at least one selected from sodium alginate, carboxymethylcellulose sodium, carrageenan, xanthan gum, sodium polyacrylate, hydroxyethyl cellulose, hydroxypropyl cellulose, pectin, tragacanth gum, gum arabic, guar gum, karaya gum, locust bean gum, gellan gum, tamarind gum, psyllium seed gum, polyvinyl alcohol, sodium chondroitin sulfate and a methoxy ethylene-maleic anhydride copolymer;
the ratio (A2/A1) of the polymer (A2) to the catechins (A1) in the hydrogel particles (A) is 1 to 4 times by weight; and
the dentifrice composition is contained in a storage container.
US Pat. No. 10,214,657

SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS

EASTMAN KODAK COMPANY, R...

1. A non-aqueous silver precursor composition consisting essentially of:at least 1 weight % of one or more (a) polymers selected from one or more of cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and carboxymethyl cellulose, based on the total weight of the non-aqueous silver precursor composition;
(b) reducible silver ions; and
(c) an organic solvent medium consisting of:
(i) one or more hydroxylic organic solvents, each of which has an ?-hydrogen atom and a boiling point at atmospheric pressure of at least 100° C. and less than 500° C., and
(ii) a nitrile-containing aprotic solvent or a carbonate-containing aprotic solvent or both a nitrile-containing aprotic solvent and a carbonate-containing aprotic solvent, all of which are different from all of the (i) one or more hydroxylic organic solvents, each having a boiling point at atmospheric pressure of at least 100° C. and less than 500° C.;
wherein the (b) reducible silver ions are present in the non-aqueous silver precursor composition in an amount of at least 0.1 weight % and up to and including 400 weight %, based on the total weight of the one or more (a) polymers.
US Pat. No. 10,214,913

POWDER BASED BALANCING LAYER

VALINGE INNOVATION AB, V...

1. A method of manufacturing a building panel with a decorative surface layer, a core and a balancing and/or protective layer, wherein the method comprises the steps:applying a first layer of a first powder based mix, comprising wood fibres and a thermosetting binder, on a core;
applying a liquid substance on the first powder based mix;
drying the first powder based mix;
turning the core with the dried first powder based mix such that the first powder based mix points downwards and an upper part of the core faces upwards;
applying a second layer on the upper part of the core; and
curing the first and second layers by providing heat and pressure, wherein the first layer forms the balancing and/or protective layer and the second layer forms the decorative surface layer in the building panel.
US Pat. No. 10,213,378

SINGLE DOSE NON-ADJUVANTED CUTANEOUS TETANUS VACCINE AND USES THEREOF

Sporos Therapeutics, LLC,...

1. A method for preventing or treating tetanus infection in a pregnant subject, comprising administering a non-adjuvanted tetanus toxoid vaccine to the skin of the subject; wherein the non-adjuvanted tetanus toxoid vaccine comprises 3% polyvinyl alcohol and 10% sucrose as excipients.
US Pat. No. 10,214,658

METHOD OF THREE-DIMENSIONAL PRINTING

LOTTE CHEMICAL CORPORATIO...

1. A method of three-dimensional (3D) printing, the method comprising:heating a composition comprising a polymer base including atactic polypropylene having a weight average molecular weight of 50,000 to 1,000,000, a density of 0.8 to 0.9 g/ml, and isotacticity (Pentad I.I, mmmm) of 5 to 20%, wherein a melting index (210° C., 2.16 kg) of the polymer base is 0.5-30 g/10 minutes;
extruding the composition as a filament; and
applying the extruded filament in one or more layers,
wherein a solidification rate (measuring melting indexes (MI, 150° C., 10 kg)) of the filament is less than or equal to 2 g/10 minutes and a melting rate (measuring melting indexes (MI, 180° C., 10 kg)) of the filament is greater than or equal to 10 g/10 minutes, and
wherein hardness of the polymer base is less than or equal to Shore A 90.
US Pat. No. 10,217,219

SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES

YALE UNIVERSITY, New Hav...

1. A computer implemented method for localizing and quantitating a particular biomarker present in individual cells of interest contained in a tissue sample, comprising:a) incubating the tissue sample with a stain that specifically labels the biomarker;
b) obtaining, using an optical imaging device, a first in-focus image and a second out-of-focus image, each of the first in-focus image and the second out-of-focus image comprising respective pixel locations having an intensity value for each pixel in the tissue sample;
c) subtracting the second out-of-focus image from the first in-focus image to obtain a third image, wherein for each pixel location a percentage of the out-of-focus image pixel intensity is subtracted from the corresponding in-focus image pixel intensity to obtain the third image; and
d) analyzing the third image to obtain a stain intensity and location of the stain so as to thereby localize and quantitate the biomarker.
US Pat. No. 10,217,475

HEADSET AND METHOD FOR CONTROLLING SAME

LG ELECTRONICS INC., Seo...

1. A headset, comprising:a wireless communication unit configured to provide wireless communication;
a first microphone mounted on the headset;
a second microphone to be placed within an ear of the user wearing the headset; and
a controller configured to:
receive a phone call via the wireless communication unit from an external device,
select either one of the first microphone or the second microphone to receive a voice signal of the user responding to the received phone call,
in response to the selection of the first microphone, receive the voice signal of the user through the first microphone, correct a sound quality of the voice signal received through the first microphone, and transmit the corrected voice signal to the external device, and
in response to the selection of the second microphone, receive the voice signal of the user from the external auditory canal of the ear of the user having the second microphone placed therein, correct a sound quality of the voice signal received through the second microphone, and transmit the corrected voice signal to the external device,
wherein the controller is further configured to:
automatically turn on a display unit of the external device, and
control the external device to display a call sound quality setting icon for setting a call sound quality on the display unit of the external device.
US Pat. No. 10,213,379

FORMULATIONS FOR THE RECTAL ADMINISTRATION OF THROMBOLYTICALLY-ACTIVE AGENTS

CENTRO DE INGENIERIA GENE...

1. A method for treating hemorrhoid disease in a human in need thereof, wherein the method consists essentially of administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a streptokinase (SK) and a pharmaceutically acceptable diluent, carrier or excipient, wherein the pharmaceutical composition is administered rectally as a suppository, wherein the SK is in an amount of 50,000 IU to 150,000 IU per gram of composition, wherein administration is for 4 to 6 days, wherein the treatment occurs without systemic thrombolytic effects, and wherein the pharmaceutical composition effectively treats hemorrhoid disease.
US Pat. No. 10,214,659

AQUEOUS COMPOSITIONS HAVING POLYALKOXYLATES FOR IMPROVED OPEN TIME

Dow Global Technologies L...

1. An aqueous composition comprising:(i) an aqueous polymer composition of one or more emulsion polymers, one or more aqueous dispersion polymers, or mixtures thereof, and
(ii) from 0.1 to 5 wt. %, based on the total weight of solids in the aqueous composition, one or more polyalkoxylates having from 2 to 15 polyalkoxylate chains and an ethylene oxide (EO) content ranging from 20 to 70 wt. %, based on the total weight of polyalkoxylate solids in the aqueous composition.
US Pat. No. 10,213,380

METHOD OF TREATING EAR PAIN

Try This First, Inc., Wa...

1. A method of treating an ear infection comprising:administering an effective amount of an antibiotic-free salivary-producing hard candy composition to an individual suffering from an ear infection,
wherein said composition comprises:
a sweetening agent;
a natural flavoring agent;
an extract; and
citric acid; and
wherein said hard candy composition is shaped to include a first surface that is convex and a second surface that is flat,
wherein said first surface is configured to fit within an oral cavity of the individual and to contact a roof of the individual's oral cavity, and
wherein the second surface is configured to contact the tongue of the individual, and
wherein the first surface and the second surface are arranged such that when the individual sucks on the hard candy composition a negative pressure is formed within the individual's oral cavity that promotes drainage of fluid from the individual's Eustachian tube.
US Pat. No. 10,214,660

TWO-COMPONENT COATING COMPOSITIONS AND COATINGS PRODUCED THEREFROM FOR IMPROVING EROSION RESISTANCE

BASF Coatings GmbH, Muen...

1. A solvent-based two-component coating composition, comprising(1) a paint base component comprising
(A) at least one polycarbonate diol,
(B) at least one hydroxyl-containing acrylate resin, polyester resin and/or polyester acrylate resin having a hydroxyl number of 75 to 500 mg KOH/g, and
(C) at least one filler modified with at least one organosilane, and
(2) a hardener component comprising
(D) at least one organic polyisocyanate,
wherein the coating composition has a viscosity of 50 to 2000 mPa·s at a shear stress of 1000 l/s and a temperature of 23° C. and a proportion of organic solvents of 100 to 350 g/L.
US Pat. No. 10,213,381

SOLID SOLUTION COMPOSITIONS AND USE IN CHRONIC INFLAMMATION

infirst Healthcare Limite...

1. A solid solution pharmaceutical composition comprising:a) 25% to 31% by weight of an ibuprofen, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof;
b) 34% to 40% by weight of a hard fat that includes a triglyceride mixture;
c) 22% to 28% by weight of a liquid lipid mixture that includes monoglyceride; and
d) 7% to 13% by weight of a liquid glycol polymer.
US Pat. No. 10,214,661

ORGANIC SILICON COATING

HUNAN SOKAN NEW MATERIALS...

1. An organic silicon coating, consisting essentially of:20 to 40 parts by weight of methyl vinyl organic silicon polymer,
1 to 6 parts by weight of methyl phenyl organic silicon polymer,
5 to 15 parts by weight of hydrogenated silicone oil,
5 to 10 parts by weight of fluorinated acrylate monomer,
5 to 15 parts by weight of silicon dioxide,
0.2 to 2 parts by weight of inhibitor,
0.1 to 1 part by weight of auxiliary,
0.1 to 1 part by weight of thermal initiator,
30 to 50 parts by weight of organic solvent,
and 2 to 5 parts by weight of metal catalyst,
wherein the inhibitor has a deblocking temperature of ?80° C. against the metal catalyst, and
wherein the auxiliary is selected from the group consisting of a leveling agent, an anti-settling agent, a wetting and dispersing agent, and combinations thereof.
US Pat. No. 10,213,383

HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS

NOVARTIS AG, Basel (CH)

1. A method for a large-scale manufacture of a squalene-containing oil-in-water emulsion, comprising steps of:(i) forming providing a first emulsion having a first average oil droplet size, wherein the first average oil droplet size is 5000 nm or less and/or wherein the number of oil droplets having a size of >1.2 ?m in the first emulsion is 5×1011/ml or less;
(ii) microfluidizing the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size, wherein the number of oil droplets having a size of >1.2 ?m in the second emulsion is 5×1010/ml or less; and
(iii) filtrating the second emulsion using a first hydrophilic polyethersulfone membrane layer having a pore size >0.3 ?m and a second hydrophilic polyethersulfone membrane layer having a pore size <0.3 ?m, thereby providing a squalene-containing oil-in-water emulsion,
wherein at least one of the first and the second hydrophilic polyethersulfone membrane layers is an asymmetric membrane,
wherein the squalene-containing oil-in-water emulsion has a volume of more than or equal to 50 liters; and,
(iv) filling the oil-in-water emulsion into one or more sterile closed systems.
US Pat. No. 10,213,895

POLISHING PAD AND METHOD FOR MANUFACTURING SAME

FUJIBO HOLDINGS, INC., C...

1. A polishing pad comprising:a resin-containing polishing cloth having a polishing cloth base impregnated with a polyurethane resin and silicon carbide, wherein
the silicon carbide has a particle diameter in a range from 0.2 to 1.5 ?m, and
the content of the silicon carbide in the resin-containing polishing cloth is in a range from 90 to 350 parts by mass relative to 100 parts by mass of the polishing cloth base.
US Pat. No. 10,214,920

COMPOSITE EPOXY RESIN BOARD AND FORMING METHOD THEREOF

GUANGDONG OUMING NEW MATE...

1. A composite epoxy resin board made from a raw material comprising following components by weight: 5% to 95% waste prepreg powders, 1% to 95% powders from waste printed circuit boards (PCBs), 1% to 90% powders from waste epoxy plastic products or phenolic plastic products, 0% to 80% stone powders, 0% to 45% PVC powders and/or PE powders and/or HDPE powders, 0% to 20% copper powders, 0% to 20% aluminum powders, 0% to 5% color pigments, 0% to 80% straw, bamboo and wood powders, 0% to 20% chemical fiber powders, 0% to 80% calcium carbonate powders, 0% to 20% adhesives, 0% to 1% antioxidants, 0% to 1% reinforcing agents, 0% to 1% carbide stabilizers, and 0% to 5% coupling agents, and a sum of which is 100%, wherein:the stone powders are made from wastes produced from marble mining or processing;
the straw, bamboo and wood powders are one or more members selected from a group consisting of straw powders, wood sawdust and bamboo sawdust;
the adhesives are one or more members selected from a group consisting of phenolic-resin adhesives, epoxy resin adhesives, isocyanate adhesives and polyvinyl alcohol adhesives.
US Pat. No. 10,214,665

METHODS FOR USING HOT MELT ADHESIVES BASED ON A BLEND OF PROPYLENE POLYMERS MADE USING SINGLE-SITE CATALYSTS

Bostik Inc., Wauwatosa, ...

1. A method of making a laminate comprising the steps of:applying a hot melt adhesive composition in a molten state to a primary substrate; and
mating a secondary substrate to the first substrate by contacting the secondary substrate with the adhesive composition, wherein the hot melt composition comprises:
(a) a polymer blend containing at least one semicrystalline LMW SSC-PP polymer and at least one essentially amorphous HMW SSC-PP copolymer; both of which are either homopolypropylene or copolymers of propylene with an ?-olefin comonomer prepared by using SSC catalysts; the weight ratio of the LMW SSC-PP polymer to the HMW SSC-PP polymer in the blends ranges from 9:1 to 1:9 and the total amount of the polymer blend in the composition of the present invention is from about 20% to about 80% by weight; the LMW SSC-PP having a weight average molecular weight from about 10,000 g/mole to about 100,000 g/mole, a crystallinity of about 18% to about 50%, and a Brookfield viscosity at 190° C. ranging from about 800 mPa·s to about 100,000 mPa·s; and the HMW SSC-PP polymer a weight average molecular weight greater than 100,000 g/mole, and a crystallinity of about 0% to about 18%, wherein the molecular weight of the HMW PP polymer is at least double the molecular weight of the LMW SSC-PP;
(b) a compatible tackifier in the amount of about 15% by weight to about 75% by weight;
(c) about 1% to about 35% by weight of a plasticizer;
(d) about 0.1% to about 3% by weight of a stabilizer or antioxidant; and
(e) optionally about 0% to about 20% by weight of a wax.
US Pat. No. 10,213,386

PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR

Pharmacyclics LLC, Sunny...

1. A solid tablet formulation comprisinga. ibrutinib, and
b. one or more pharmaceutically acceptable excipients,
wherein the ibrutinib is present in an amount of at least about 50% w/w, and
wherein oral administration of one or more tablet(s) of the solid tablet formulation in an amount sufficient to deliver 560 mg of ibrutinib to a population of healthy human adults in a fasted state results in a mean AUC0-? of about 465 ng*h/ml+/?248 ng*h/ml.
US Pat. No. 10,213,387

ORAL DRUG DELIVERY SYSTEM

Sun Pharma Advanced Resea...

1. An orally administerable drug delivery system in the form of a coated tablet, comprising:(1) a core comprising one or more active ingredient composition layers and one or more separate reactive composition layers,
(i) the one or more active ingredient composition layers comprising at least one therapeutically active ingredient and at least one pharmaceutically acceptable excipient, wherein in at least one active ingredient composition layer, at least one pharmaceutically acceptable excipient is a rate controlling excipient and
(ii) the reactive composition layer comprising a reactive ingredient; and
(2) a water insoluble polymer coating surrounding the core and capable of being dissolved, disintegrated, or weakened in the presence of the reactive ingredient released from the reactive composition,
wherein one or more of the reactive composition layers is located in an immediate vicinity of one or more preselected portions of the coating in order to be in communication with said preselected portions of the coating, and the one or more therapeutically active ingredient composition layers are in the vicinity of another portion of the coating; and
wherein the at least one or more preselected portions of the coating that is in communication with the reactive layer is removed after contact with an aqueous environment and wherein the remaining portion of the coating is not removed.
US Pat. No. 10,213,132

METHOD TO EVALUATE PATIENTS FOR THORACIC OUTLET SYNDROME

Vanguard Specialty Imagin...

1. A method of generating and outputting a plurality of three-dimensional models and a plurality of series of images to evaluate a human subject for a presence or absence of thoracic outlet syndrome (TOS) which method comprises:generating a first three-dimensional model of a brachial plexus on an affected side(s), the first three-dimensional model generated based at least in part on reconstruction and reformation of a first set of magnetic resonance imaging (MRI) slices obtained in each of three planes, in the absence of a contrast agent, with a subject in a supine position with both arms in a neutral position by a side of a body of the subject, wherein obtaining the first set of MRI slices is configured to comprise:
obtaining a gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises sagittal slices that cover scalene triangle, costoclavicular space, and retropectoralis spaces on an affected side(s);
obtaining another gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises axial slices that cover mid and lower cervical spinal portions, lower neck, the brachial plexus, supraclavicular space, superior mediastinum, and lung apex on the affected side(s); and
obtaining a Short Tau Inversion Recovery (STIR) sequence that comprises slices that cover a volume of the brachial plexus on the affected side(s);
outputting a first series of images including the first set of MRI slices, to be displayed on a workstation to determine, based at least in part on the first set of MRI slices, a presence or absence of stenosis and to determine the presence or absence of thoracic outlet syndrome (TOS);
outputting the first three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS);
obtaining a second set of MRI slices obtained in one or more planes, in the absence of the contrast agent, with the subject in a supine position with both arms placed in abduction and external rotation, by imaging upper chest and neck portions and a supraclavicular fossa region on the affected side(s), wherein the second set of MRI slices is configured to be obtained by the gradient echo T1, spin echo T1, or fast spin echo T2-weighted sequence that comprises sagittal slices that cover scalene triangle, costoclavicular space and retropectoralis space on the affected side(s);
outputting a second series of images including the second set of MRI slices, to be displayed on the workstation to determine, based at least in part on the second set of MRI slices, the presence or absence of stenosis and to determine the presence or absence of thoracic outlet syndrome (TOS);
generating a second three-dimensional model of arteries on the affected side(s), the second three-dimensional model generated based at least in part on reconstruction and reformation of a plurality of slices from a contrast-enhanced magnetic resonance angiogram (MRA), wherein the plurality of MRA slices images subclavian and axillary arteries on both sides of the subject, wherein the plurality of MRA slices are configured to be obtained by administering a diluted contrast agent comprising 50% gadolinium into a vein on a first side of the subject such that the contrast agent enters arteries on both sides of the subject and veins on both sides of the subject and obtaining a contrast-enhanced MRA, which images, in the subject, the contrast agent;
outputting a third series of images including the plurality of MRA slices, to be displayed on the workstation to determine, based at least in part on the plurality of MRA slices, a presence or absence of stenosis, external compression, or aneurysm, if any, in each of the subclavian and the axillary arteries by assessing vascular contrast enhancement, on both sides of the subject and to determine the presence or absence of thoracic outlet syndrome (TOS);
outputting the second three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS);
generating a third three-dimensional model of veins on the affected side(s), the third three-dimensional model generated based at least in part on reconstruction and reformation of a plurality of slices from a magnetic resonance venogram (MRV), wherein the plurality of MRV slices images the subclavian, axillary, and brachiocephalic veins on both sides of the subject, wherein the plurality of MRV slices are configured to be obtained by administering the diluted contrast agent comprising 50% gadolinium into the vein on the first side of the subject such that the contrast agent enters arteries on both sides of the subject and veins on both sides of the subject and obtaining the MRV, which images, in the subject, the contrast agent;
outputting a fourth series of images including the plurality of MRV slices, to be displayed on the workstation to determine, based at least in part on the plurality of MRV slices, the presence or absence of stenosis or external compression in each of the subclavian, axillary, and brachiocephalic veins on both sides of the subject by assessing vascular contrast enhancement, on both sides of the subject and to determine the presence or absence of thoracic outlet syndrome (TOS); and
outputting the third three-dimensional model to the workstation to determine the presence or absence of thoracic outlet syndrome (TOS).
US Pat. No. 10,213,388

ABUSE RESISTANT ORAL DOSAGE FORMS

Elite Laboratories, Inc.,...

1. A compressed microtablet that is coated with a membrane, comprisinga compressed uncoated microtablet having a major dimension that is about 0.5 to about 3. 0 mm and is a compression of a dry powder blend comprising at least one opioid antagonist, at least one compression aid, and at least one lubricant;
wherein the uncoated microtablet comprises about 10 to about 30 weight percent, by weight of the uncoated microtablet, of the at least one opioid antagonist;
wherein the at least one opioid antagonist is naltrexone, naloxone, nalmephene, cyclazacine, or levallorphan and is dispersed substantially throughout said uncoated microtablet,
wherein the at least one compression aid is microcrystalline cellulose, lactose, dicalcium phosphate, sucrose, starch, stearic acid, polyethylene glycol, a wax, or a combination thereof; and
wherein the at least one lubricant is calcium strearate, magnesium stearate, zinc stearate, strearic acid, talc, hydrogenated vegetable oil, or a combination thereof;
a membrane coating the compressed uncoated microtable, wherein the membrane is about 16 to about 80 weight percent, by weight of the coated microtablet, the membrane comprising:
about 2 weight percent to about 89 weight percent, by weight of the membrane, of a water-retardant polymer that is a non-ionic poly(ethylacrylate-co-methacrylate) polymer in which the molar ratio of ethyl acrylate to methyl methacrylate is about 2:1; and
about 5 weight percent to about 50 weight percent, by weight of the membrane, of an additive that is calcium stearate, magnesium stearate, zinc stearate, stearic acid, glyceryl monostearate, hydrogenated vegetable oil, talc, or a combination thereof;
wherein the weight gain of the uncoated microtablet after the application of the membrane is from about 105 to about 500 weight percent increase;
and
an opioid agonist layer coated onto the membrane, wherein the opioid agonist comprises oxycodone, morphine, hydrocodone, or codeine;
wherein said coated microtablet releases no more than about 0.5 weight percent of said opioid antagonist within 36 hours when measured using the USP Apparatus I (Basket) Method at 100 rpm at 37° C. in simulated gastric fluid for one hour followed by simulated intestinal fluid thereafter.
US Pat. No. 10,214,668

ADHESIVE COMPOSITION AND ARTICLE INCLUDING THE SAME

ND Industries, Inc., Cla...

14. An article comprising:a substrate having a surface; and
an adhesive composition disposed on said surface;
wherein said adhesive composition is as set forth in claim 12.
US Pat. No. 10,217,999

RECHARGEABLE LITHIUM BATTERY

Samsung SDI Co., Ltd., Y...

1. A rechargeable lithium battery, comprising:a negative electrode and a positive electrode,
wherein a specific surface area per a unit area of the positive electrode is 3 times to about seven times as large as a specific surface area per a unit area of the negative electrode,
wherein the specific surface area per the unit area of the positive electrode is calculated from a specific surface area and amount of each component of the positive electrode and a loading level of the positive electrode, and
wherein the specific surface area per the unit area of the negative electrode is calculated from a specific surface area and amount of each component of the negative electrode and a loading level of the positive electrode.
US Pat. No. 10,213,389

CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

Recro Gainesville LLC, G...

1. A hard gelatin capsule comprising:a population of isosorbide dinitrate immediate-release beads comprising: isosorbide dinitrate in an amount from about 2.5 mg to about 30 mg, mannitol, povidone, silicon dioxide, and sugar spheres;
a population of isosorbide dinitrate sustained-release beads comprising: isosorbide dinitrate in an amount from about 2.5 mg to about 30 mg, mannitol, povidone, silicon dioxide, sugar spheres, triethyl citrate, an ammonio methacrylate copolymer, and a methacrylic acid copolymer;
a population of hydralazine immediate-release beads comprising: hydralazine, or a salt thereof, in an amount from about 0.5 mg to about 60 mg, povidone, silicon dioxide, sugar spheres, and citric acid; and
a population of hydralazine sustained-release beads comprising: hydralazine, or a salt thereof, in an amount from about 2.5 mg to about 30 mg, povidone, silicon dioxide, sugar spheres, citric acid, an ammonio methacrylate copolymer, a methacrylic acid copolymer, and triethyl citrate.
US Pat. No. 10,214,669

COMPOSITIONS COMPRISING 2,3-DICHLORO-1,1,1-TRIFLUOROPROPANE, 2-CHLORO-1,1,1-TRIFLUOROPROPENE, 2-CHLORO-1,1,1,2-TETRAFLUOROPROPANE OR 2,3,3,3-TETRAFLUOROPROPENE

THE CHEMOURS COMPANY FC, ...

1. A composition comprising HFO-1234yf, HFC-245cb, HFC-245fa, HFO-1234ze, HCFO-1233zd and HCFO-1233xf.
US Pat. No. 10,213,390

TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

ZYNERBA PHARMACEUTICALS, ...

1. A method of treating a human suffering from Fragile X Syndrome comprising:administering a therapeutically effective amount of synthetic or purified cannabidiol to the human suffering from Fragile X Syndrome to effectively treat the Fragile X Syndrome in the human in need thereof.
US Pat. No. 10,218,001

OLIVINE OXIDE-CONTAINING POSITIVE ACTIVE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY WITH IMPROVED ELECTRO-CONDUCTIVITY, RATE CHARACTERISTICS AND CAPACITY CHARACTERISTICS, METHOD FOR MANUFACTURING THE SAME, AND RECHARGEABLE LITHIUM BATTERY INCLUDING THE SAM

Samsung SDI Co., Ltd., G...

1. A rechargeable lithium battery comprising:a positive electrode comprising a positive active material, the positive active material comprising:
a composite oxide represented by the following Chemical Formula 1:
LixMyM?zXO4-wAw  [Chemical Formula 1]
wherein, in Chemical Formula 1,
M and M? are independently selected from the group consisting of iron (Fe), aluminum (Al), boron (B), cobalt (Co), chromium (Cr), copper (Cu), gallium (Ga), germanium (Ge), hafnium (Hf), magnesium (Mg), manganese (Mn), molybdenum (Mo), niobium (Nb), nickel (Ni), tin (Sn), titanium (Ti), vanadium (V), zinc (Zn), zirconium (Zr), and a combination thereof,
X is selected from the group consisting of phosphorus (P), arsenic (As), bismuth (Bi), molybdenum (Mo), antimony (Sb), and a combination thereof,
A is selected from the group consisting of fluorine (F), sulfur (S), and a combination thereof, and
0 germanium (Ge) metal, gallium (Ga) metal, or a combination thereof adhered to a surface of the composite oxide;
a negative electrode comprising a negative active material; and
an electrolyte.
US Pat. No. 10,213,391

PHARMACEUTICAL COMPOSITIONS COMPRISING HEMP AND TURMERIC TO TREAT PAIN AND INFLAMMATION

1. A tablet or capsule consisting essentially of curcumin, cannabidiol, talc, methacrylic acid-ethyl acrylate copolymer, triethyl citrate, and a simethicone emulsion.
US Pat. No. 10,214,671

REFRIGERATOR OIL AND WORKING FLUID COMPOSITION FOR REFRIGERATOR

1. A working fluid composition for a refrigerating machine, consisting of:a refrigerating machine oil consisting of a base oil and optionally an additive, wherein the base oil comprises an ester of a polyhydric alcohol and a fatty acid with a content of a C5-C9 branched fatty acid of 70-100% by mole, wherein the polyhydric alcohol is a mixture of pentaerythritol and di-(pentaerythritol); and
a refrigerant consisting of only one fluoropropene refrigerant.
US Pat. No. 10,218,002

POSITIVE ELECTRODE MIX FOR SECONDARY BATTERIES INCLUDING IRREVERSIBLE ADDITIVE

LG Chem, Ltd., (KR)

1. A positive electrode mix for secondary batteries comprising an irreversible additive that decreases irreversible efficiency of a positive electrode active material and a positive electrode,wherein the irreversible additive is a lithium molybdenum sulfide represented by Formula 1 below:
Li2+xMo6-yMyS8-z  (1),
wherein ?0.1?x?0.5, 0?y?0.5, ?0.1?z?0.5, and M is a metal or transition metal cation having an oxidation number of +2 to +4, and
the irreversible additive has an operation voltage of 1.0 V to 2.5 V with respect to Li, and
wherein the positive electrode mix further comprises a positive electrode active material comprising a lithium transition metal oxide represented by Formula 2 or 3 below:
LixMyMn2-yO4-zAz  (2),
wherein in Formula 2:
M is at least one element selected from the group consisting of Al, Mg, Ni, Co, Fe, Cr, V, Ti, Cu, B, Ca, Zn, Zr, Nb, Mo, Sr, Sb, W, Ti and Bi;
A is at least one monovalent or divalent anion; and
0.9?x?1.2, 0 (1?x)LiM?O2-yAy-xLi2MnO3-y?Ay?  (3),
wherein in Formula 3:
M? is MnaMb;
M is at least one selected from the group consisting of Ni, Ti, Co, Al, Cu, Fe, Mg, B, Cr, Zr, Zn and Period II transition metals;
A is at least one selected from the group consisting of anions such as PO4, BO3, CO3, F and NO3; and
0
US Pat. No. 10,218,003

ANODE AND SECONDARY BATTERY INCLUDING THE SAME

Samsung SDI Co., Ltd., Y...

1. An anode for a secondary battery, the anode comprising:a negative electrode active material layer on a current collector, the negative electrode active material layer comprising:
a negative electrode active material, a binder, and a conductive material, wherein the negative electrode active material comprises at least one pore on a surface thereof, and the conductive material is located at the pore of the negative electrode active material,
wherein the conductive material has a diameter of 10 nm to 50 nm, and
wherein the pore of the negative electrode active material has a width of 50 nm to 10 ?m, and a depth of 20 nm to 10 ?m.
US Pat. No. 10,213,393

COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE

1. A method of treating Parkinson's disease in a patient, comprising:i) administering to the patient once daily in the morning a pharmaceutical composition comprising about 129 mg of amantadine free base equivalent for one week;
ii) increasing the dose of amantadine by administering to the patient once daily in the morning a pharmaceutical composition comprising about 193 mg of amantadine free base equivalent;
wherein each of the pharmaceutical compositions comprises i) an extended release component comprising amantadine free base equivalent; and ii) an immediate release component comprising about 48 mg of amantadine free base equivalent, wherein each of the pharmaceutical compositions is an osmotic device comprising an osmotic agent and an osmotic coating,
wherein the maximum daily dose of amantadine is about 322 mg of amantadine free base equivalent,
wherein each of the pharmaceutical compositions provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is between about 40% and about 70% of the dC/dT provided by the same quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, and
wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.
US Pat. No. 10,214,673

THERMALLY CONDUCTIVE, PLATE-SHAPED PIGMENT COATED WITH ALUMINIUM OXIDE

MERCK PATENT GMBH, Darms...

1. A thermally conductive pigment consisting of a flake-form, dielectric substrate and a single layer located thereon, said single layer comprises at least 80% by weight, based on the total weight of the layer, of aluminium oxide and/or aluminium oxide hydrate and 0.1 to 10% by weight, based on the total weight of the layer, of MgO, Cr2O3 or SiO2; andwherein the substrate is selected from the group consisting of natural mica flakes, synthetic mica flakes, kaolin flakes, talc flakes and mixtures thereof.
US Pat. No. 10,213,394

COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE

1. A method of treating a drug-induced extrapyramidal reaction in an adult patient, comprising:i) administering to the patient once daily in the morning a pharmaceutical composition comprising about 129 mg of amantadine free base equivalent for one week;
ii) increasing the dose of amantadine by administering to the patient once daily in the morning a pharmaceutical composition comprising about 193 mg of amantadine free base equivalent;
wherein each of the pharmaceutical compositions comprises i) an extended release component comprising amantadine free base equivalent; and ii) an immediate release component comprising about 48 mg of amantadine free base equivalent, wherein each of the pharmaceutical compositions is an osmotic device comprising an osmotic agent and an osmotic coating,
wherein the maximum daily dose of amantadine is about 322 mg of amantadine free base equivalent,
wherein each of the pharmaceutical compositions provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is between about 40% and about 70% of the dC/dT provided by the same quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, and
wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.
US Pat. No. 10,213,396

PATCH TO ENHANCE LOCALLY FAT METABOLISM, USING THERMOPLASTIC ELASTOMER GEL COMPOSITION INCLUDING CAPSAICIN

SENNY STUDIO CO., LTD., ...

1. A patch to enhance locally fat metabolism, using a thermoplastic elastomer (TPE) gel composition including capsaicin, which is applied to the skin surface, comprising:a skin adhering layer formed of 3˜12 wt % of styrene ethylene butylene styrene (SEBS) or styrene ethylene ethylene propylene styrene (SEEPS), 44˜53 wt % of an adhesive agent; 44˜53 wt % of mineral oil, and 0.001˜0.009 wt % of capsaicin, the skin adhering layer having a top surface and a bottom surface;
a base layer secured to the bottom surface of the skin adhering layer, to provide support for the patch; and
a removable paper/film layer secured to the top surface of the skin adhering layer, to protect the skin adhering layer prior to use.
US Pat. No. 10,213,397

MICROTUBULE POLYMERIZATION MODULATORS FOR TREATING LMNA-RELATED DILATED CARDIOMYOPATHY

Northwestern University, ...

1. A method for treating lamin A/C (LMNA)-related dilated cardiomyopathy (DCM) in a subject in need thereof, the method comprising administering an effective amount of a modulator of microtubule polymerization.
US Pat. No. 10,215,701

METHOD OF ASSESSING CHEMICALS IN PRODUCED FLUIDS

Lux Assure Limited, Edin...

1. A method of monitoring water-soluble treatment chemicals in a fluid that is immiscible with water and which may or may not contain some aqueous fluid, where said water-soluble treatment chemical is a hydrate inhibitor, the method comprising:a. obtaining a sample of said fluid;
b. adding a first reagent to the fluid sample, wherein the first reagent is an oxidising agent being reactive with the treatment chemical to produce a first product, wherein the first product is an aldehyde;
c. adding a second reagent to the fluid sample, wherein the second reagent is an aldehyde reactive reagent being reactive with the first product in step (b) to produce an optically detectable second product wherein the second reagent is Fluoral P; and
d. detecting an optically detectable product;wherein the detection step takes place without separation of the aqueous phase containing the treatment chemicals from the fluid immiscible with water.
US Pat. No. 10,213,398

METHODS FOR ALLEVIATING STATIN MYOPATHY

1. A pharmaceutical formulation comprising a statin side effect-alleviating amount of ?-hydroxy ?-methylbutyrate (HMB), or a pharmaceutically acceptable salt thereof, in combination with:(a) 10 to 80 mg atorvastatin;
(b) 5 to 40 mg rosuvastatin;
(c) 10 to 80 mg pravastatin;
(d) 5 to 80 mg simvastatin;
(e) 10 to 80 mg lovastatin;
(f) 1 to 4 mg pitavastatin; or
(g) 20 to 80 mg fluvastatin;
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,214,678

COMPOSITIONS AND METHOD FOR TREATING OUT HYDROGEN SULFIDE AND PREVENTING SETTLING OF PRECIPITATE IN AN ENVIRONMENTALLY RESPONSIBLE DRILLING AND PACKER FLUID

Halliburton Energy Servic...

1. A fluid for use in the presence of hydrogen sulfide in a subterranean formation, comprising:an oleaginous base;
an additive comprising at least one ferrous based compound selected from the group of consisting of ferrous lactate, ferrous bis glycinate, ferrous citrate, ferrous acetate, ferrous fumarate, ferrous succinate, ferrous sacchrate, ferrous tartarate, ferrous glycine sulfate, ferrous glutamate, ferrous ascorbate, ferrous polymaltose, and combinations thereof; and
a viscosifier, such that the product of any reaction of the ferrous based compound with any hydrogen sulfide in the fluid will remain in suspension in the fluid.
US Pat. No. 10,213,399

COMPOSITIONS AND METHODS OF USE OF ?-HYDROXY-?-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY

Metabolic Technologies, I...

1. A method of modulating autophagy in a mammal comprising administering to the mammal from about 0.5 g to about 30 g of ?-hydroxy-?-methylbutyric acid (HMB), wherein upon said administration of said HMB to the mammal, autophagy is modulated in adipocytes.
US Pat. No. 10,213,400

METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS

JAZZ PHARMACEUTICALS IREL...

1. A method for reducing adverse effects caused by a combination of gamma-hydroxybutyrate (GHB) or a salt thereof and divalproex sodium in a patient comprising:administering a reduced daily dosage amount of GHB or a salt thereof to the patient of between about 5% to about 35%, compared to a daily dosage amount of GHB or salt thereof administered to the patient in the absence of concomitant administration of divalproex sodium;
wherein the patient is concomitantly administered divalproex sodium;
wherein the patient is a patient suffering from cataplexy in narcolepsy or excessive daytime sleepiness in narcolepsy and currently taking GHB or salt thereof;
wherein the daily dosage amount of GHB or salt thereof administered to the patient in the absence of concomitant administration of divalproex sodium is between 4.5 g to 9 g.
US Pat. No. 10,214,426

OLIGOMERIZATION OF ETHYLENE TO LIQUID TRANSPORTATION FUELS WITH POST SYNTHESIS TREATED ZSM-5 CATALYST

Phillips 66 Company, Hou...

1. An oligomerization process to produce transportation fuels, the process comprising directing a feed stream comprising ethylene to a reactor that contains a fixed bed of ZSM-5 catalyst that is essentially free of catalyst metals other than silica and alumina, wherein the ZSM-5 catalyst is supported by an alumina binder, wherein prior to the oligomerization, the ZSM-5 catalyst is provided with a post synthesis treatment comprising a base wash to resist coke formation in the zeolite crystallites and extend catalyst life, wherein the oligomerization is conducted at a pressure between 0 psig and 800 psig, a temperature of between 260° C. and 420° C., and a gas hourly space velocity of between 1000 and 5000 inverse hours and wherein at least 85% of the ethylene is converted.
US Pat. No. 10,213,405

OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES

ALLERGAN, INC., Irvine, ...

1. A topical ophthalmic composition for the treatment of dry eye comprising:water;
a tonicity component selected from erythritol, carnitine, isomers thereof, and suitable salts thereof;
carboxymethyl cellulose or its suitable salt, or a combination of carboxymethylcellulose or its suitable salt and hyaluronic acid; and
glycerol;
wherein the composition is effective for the treatment of dry eye.
US Pat. No. 10,214,429

PHOSPHOR CONTAINING CE

Panasonic Intellectual Pr...

1. A phosphor comprising a crystal phase having a chemical composition CexM3-x-y?6?11-z, whereM is one or more elements selected from the group consisting of Sc, Y, La, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu;
? contains Si in an amount of 50 mol % or more of a total mol of ?;
? contains N in an amount of 80 mol % or more of a total mol of ?;
0 0?y?1.0; and
0?z?1.0, wherein
the phosphor shows:
a maximum peak of an emission spectrum in a wavelength range of 600 nm or more and 800 nm or less; and
a first peak of an excitation spectrum in a wavelength range of 500 nm or more and 600 nm or less.
US Pat. No. 10,214,688

METHOD FOR PRODUCING FLUORIDE FLUORESCENT MATERIAL

NICHIA CORPORATION, Anan...

1. A method for producing a fluoride fluorescent material, the method comprising mixing together a first solution containing at least first complex ions comprising tetravalent manganese and hydrogen fluoride, a second solution containing at least potassium ions and hydrogen fluoride and a third solution containing at least second complex ions comprising at least one element selected from the group consisting of elements belonging to Groups 4 and 14 of the Periodic Table and fluorine ions, whereinthe fluoride fluorescent material comprises a chemical composition represented by the following formula (I):
K2[M1?aMn4+aF6]  (I),
M is at least one element selected from the group consisting of elements belonging to Groups 4 and 14 of the Periodic Table, and a is a value that satisfies the relationship: 0 a minimum value of a weight median diameter of the fluoride fluorescent material is greater than or equal to 30 ?m.
US Pat. No. 10,212,897

SOYBEAN CULTIVAR S170001

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170001, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124453.
US Pat. No. 10,212,898

PLANTS WITH AN INTENSE FRUIT PHENOTYPE

NUNHEMS B.V., Nunhem (NL...

1. A Solanum lycopersicum plant or plant cell, tissue or plant part thereof comprising a reduced amount, activity or function of AGL11-like protein, wherein the AGL11-like protein has at least 95% amino acid sequence identity to SEQ ID NO: 3 wherein the plant does not have a deletion from nucleotide 1042 to nucleotide 637 upstream of the ATG start codon of SEQ ID NO: 1, and wherein the plant has an intense phenotype.
US Pat. No. 10,213,410

PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND ADP RECEPTOR ANTAGONIST, PREPARATION METHOD THEREOF AND USE THEREOF

CHENGDU BAIYU PHARMACEUTI...

1. A pharmaceutical composition, comprising Ginkgolide B and Ticagrelor, wherein a weight ratio of Ginkgolide B to Ticagrelor is in a range of from 1:500 to 1:25.
US Pat. No. 10,214,434

METHOD FOR THE TREATMENT OF METALS

Global Ecoprocess Service...

1. A method for precipitating metal waste in form of metal borates, wherein the waste which contains dissolved metal salts, is mixed with a boron compound, and the pH is adjusted to a value at which hydroxide precipitates of a first metal are formed to act as precipitation nuclei for formation of the metal borates, andwherein the pH is further adjusted to increase gradually for precipitating a second or further metals contained in the waste in form of metal borates.
US Pat. No. 10,212,899

SOYBEAN VARIETY 01062052

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 01062052, wherein a sample of seed of said variety has been deposited under ATCC Accession No. PTA-124995.
US Pat. No. 10,213,155

METHOD AND APPARATUS FOR PROCESSING USER LACTATE LEVEL INFORMATION

Nokia Technologies Oy, E...

1. A method, comprising:receiving, from a wearable sensor, current lactate level information of a user performing physical exercise;
setting, by the user, a target fatigue value for the physical exercise;
determining with a lactate level extraction and processing method target lactate level information based on the target fatigue value;
receiving characteristics of the physical exercise comprising information of an end exhaustion level of the physical exercise measured by lactate acid in a body of the user during the physical exercise;
determining adjusted characteristics comprising adjustments to at least one of a route and a speed of the physical exercise in order to match the current user lactate level information in the end of the physical exercise with the target lactate level information, based on the current lactate level information of the user, the target lactate level information and the characteristics for the physical exercise; and
outputting feedback comprising an indication of the adjusted characteristics of the physical exercise causing the user to adjust the at least one of a route and a speed of the physical exercise based on the adjusted characteristics.
US Pat. No. 10,213,411

USE OF PRODRUGS OF FUMARATES IN TREATING HEART FAILURE DISEASES

1. A method of treating heart failure with preserved ejection fraction in a subject having heart failure with preserved ejection fraction, the method comprising administering to the subject a therapeutically effective amount of one or more prodrugs of monomethyl fumarate or a pharmaceutically acceptable salt, polymorph, hydrate, solvate, or co-crystal thereof.
US Pat. No. 10,214,435

NON-EMULSIFIER FOR COMPLETION BRINES TO PREVENT EMULSION FROM FORMING

M-I L.L.C., Houston, TX ...

8. A method comprising:emplacing a wellbore fluid into a wellbore, the wellbore fluid comprising:
a base fluid;
one or more sorbitan esters;
one or more non-ionic surfactants; and
one or more amphoteric surfactants,
wherein the ratio of the one or more sorbitan esters to the one or more non-ionic surfactants to the one or more amphoteric surfactants is in the range of 1:2.5:1.6 to 1:5:3.
US Pat. No. 10,212,900

SWEET CORN HYBRID SVSC0111 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SHW6S-14IW11, a sample of seed of said line having been deposited under ATCC Accession Number PTA-124216.
US Pat. No. 10,212,901

SOYBEAN VARIETY 01068895

Monsanto Technology LLC, ...

1. A plant of soybean variety 01068895, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124837.
US Pat. No. 10,212,902

SOYBEAN VARIETY 01067523

Monsanto Technology LLC, ...

1. A plant of soybean variety 01067523, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124979.
US Pat. No. 10,212,903

SOYBEAN VARIETY 5PFDE97

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PFDE97, representative seed of the variety having been deposited under ATCC Accession Number PTA-123780.
US Pat. No. 10,212,904

MAIZE INBRED PH42WT

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH42WT, representative seed of the variety having been deposited under ATCC accession number PTA-124778.
US Pat. No. 10,212,905

MAIZE INBRED PH41DJ

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH41DJ, representative seed of the variety having been deposited under ATCC accession number PTA-124810.
US Pat. No. 10,217,514

SEMICONDUCTOR MEMORY DEVICE

TOSHIBA MEMORY CORPORATIO...

1. An operation method for a semiconductor memory device,the device including:
a first electrode;
a second electrode; and
a memory cell provided between the first electrode and the second electrode, the memory cell including a resistance change film,
the method comprising:
when performing a writing operation for the memory cell to cause a resistive state of the memory cell to transition,
applying a first voltage of a first polarity to the first electrode;
applying a second voltage of a second polarity opposite from the first polarity to the second electrode; and
after the first voltage is applied to the first electrode, continuously applying a third voltage of the first polarity to the first electrode while the second voltage is applied to the second electrode,
the third voltage having an absolute value smaller than an absolute value of the first voltage.
US Pat. No. 10,212,906

MAIZE HYBRID X13M651

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X13M651, representative seed produced by crossing a first plant of variety PH41R5 with a second plant of variety PH2STM, wherein representative seed of the varieties PH41R5 and PH2STM have been deposited under ATCC Accession Numbers PTA-124793 and PTA-124413, respectively.
US Pat. No. 10,213,418

THERAPEUTIC USES OF BERBERINE FORMULATIONS

TWi Biotechnology, Inc., ...

1. A method of treating and/or preventing dermatologic toxicities induced by targeted therapy comprising topically administering to a subject in need thereof a pharmaceutically effective amount of a topical pharmaceutical composition comprising berberine, wherein said targeted therapy is selected from the group consisting of MEK inhibitors, HER2 inhibitors and mTOR inhibitors, and wherein berberine is the only pharmaceutically acceptable active component.
US Pat. No. 10,212,907

LETTUCE CULTIVAR LOCKWOOD

VANGUARD SEED, INC., Sal...

1. A seed of lettuce cultivar Lockwood, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-124028.
US Pat. No. 10,214,443

LITHIUM SILICATE MATERIALS

Ivoclar Vivadent AG, Sch...

1. A lithium silicate glass ceramic material formed by:a) heating a starting glass material which is essentially free of ZnO and comprises SiO2, LiO2, K2O, Al2O3, nucleating agent, and optionally Me(II)O, wherein Me is CaO, BaO, MgO, SrO or combinations thereof, at a first temperature of 500 to 600° C. such that nuclei suitable to form lithium metasilicate crystals are formed; and
b) heating the material formed after step a) at a second temperature of 680 to 720° C. to produce a lithium silicate glass ceramic which has lithium metasilicate as the main crystalline phase, and wherein the crystals are of lamellar or platelet form,
wherein the material formed after step b) is convertible to a lithium silicate glass ceramic having disilicate as the main crystalline phase by heating to a third temperature which is higher than the second temperature.
US Pat. No. 10,212,908

MALE STERILITY IN CATHARANTHUS

BALL HORTICULTURAL COMPAN...

1. A Catharanthus roseus plant comprising a nuclear recessive allele, wherein the nuclear recessive allele confers male-sterility, wherein Catharanthus roseus line P7998D comprises the nuclear recessive allele, and wherein representative seed of Catharanthus roseus line P7998D has been deposited under ATCC Accession No. PTA-122493.
US Pat. No. 10,214,700

METHODS UTILIZING DURABLE FUNCTIONAL MATERIALS FOR CHEMICAL PROCESSES THAT INCLUDE AN OXIDATION STEP

Arizona Board of Regents ...

1. A method, comprisingcontacting a redox active oxygen carrier material with a fluid stream to reduce a redox active metal oxide in the redox active oxygen carrier material and oxidize a component in the fluid stream; and
contacting the redox active oxygen carrier material with a second fluid stream to oxidize the reduced redox active metal;
wherein redox active oxygen carrier material comprises a redox active metal ion atomically dispersed in a zirconia or yttria-stabilized zirconia matrix.
US Pat. No. 10,212,909

ARTICHOKE VARIETY NUN 04455 ARA

NUNHEMS B.V., Nunhem (NL...

1. A hybrid plant, plant part or seed of Artichoke variety NUN 04455 ARA, wherein a representative sample of seed of said variety is deposited under Accession Number NCIMB 42843.
US Pat. No. 10,212,910

SOYBEAN VARIETY 5PVGJ25

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PVGJ25, representative seed of the variety having been deposited under ATCC Accession Number PTA-125068.
US Pat. No. 10,213,422

COMPOSITIONS AND METHODS OF INHIBITING HISTONE DEACETYLASES

Yale University, New Hav...

1. A method for treating pulmonary hypertension in a subject in need thereof comprising administering to the subject a composition comprising tasquinimod or a salt or solvate thereof.
US Pat. No. 10,218,033

BATTERIES AND ELECTROLYTES INCORPORATING FLUOROETHYLENE CARBONATE

Google LLC, Mountain Vie...

1. A battery comprising:an anode, wherein the anode comprises silicon monoxide (SiO);
a cathode, wherein the cathode comprises lithium cobalt oxide (LCO);
a separator, wherein the separator comprises an electrically-insulating material;
a solid electrolyte interphase (SEI) layer, wherein the SEI layer comprises at least one of: lithium carbonate (Li2CO3) or lithium oxide (Li2O); and
an electrolyte, wherein the electrolyte comprises a salt dissolved in a solvent and at least one additive, wherein the salt comprises lithium hexafluorophosphate (LiPF6), wherein the solvent comprises ethylene carbonate (EC) and diethylene carbonate (DEC) in about a 1:2 volume ratio, and wherein the additive comprises fluoroethylene carbonate (FEC) in an 8-12% weight ratio wherein the solid electrolyte interphase layer is between the electrolyte and a surface of the anode.
US Pat. No. 10,212,911

ENDOPHYTES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE THEREOF

Indigo Agriculture, Inc.,...

1. A synthetic combination comprising a purified microbial population in association with a plurality of seeds or seedlings of an agricultural plant, wherein the purified microbial population comprises a first endophyte capable of production of acetoin, wherein the first endophyte is of the genus Cladosporium and comprises an ITS rRNA nucleic acid sequence comprising SEQ ID NO: 3694, and wherein the first endophyte is present in the synthetic combination in an amount effective to provide a benefit to the seeds or seedlings or the plants derived from the seeds or seedlings.
US Pat. No. 10,213,423

CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS

AROG PHARMACEUTICALS, INC...

1. A method for treating a FLT3 mutated proliferative disorder in a patient that comprises administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the proliferative disorder is a hematological malignancy.
US Pat. No. 10,214,703

LUBRICANTS WITH ZINC DIALKYL DITHIOPHOSPHATE AND THEIR USE IN BOOSTED INTERNAL COMBUSTION ENGINES

AFTON CHEMICAL CORPORATIO...

1. An engine oil composition for use in a boosted internal combustion engine, said engine oil composition comprising:greater than 50 wt. % of a base oil of lubricating viscosity; and
an additive composition comprising:
one or more overbased calcium-containing detergents having a total base number of greater than 225 mg KOH/g, measured by the method of ASTM D-2896, and
one or more zinc dialkyl dithiophosphate compounds, wherein the one or more zinc dialkyl dithiophosphate compounds are derived from a molar ratio of secondary alcohol to primary alcohol of from 0:100 to 100:0, and have an average total carbon content of 12 to 15 moles of carbon atoms per mole of phosphorus,
the engine oil composition includes an amount of the overbased calcium-containing detergent that provides 1100 ppm by weight to less than 1800 ppm by weight of calcium to the engine oil composition, and 0.01 wt. % to 5 wt % of the zinc dialkyl dithiophosphate, both amounts being based on a total weight of the engine oil composition, and
the engine oil composition contains 0.085 wt. % or less of phosphorus, based on a total weight of the engine oil composition, and
the engine oil composition contains a sufficient amount of an oil soluble molybdenum compound to provide 5 ppm by weight to 300 ppm by weight of molybdenum to the engine oil composition, based on a total weight of the engine oil composition, and
where the engine oil composition comprises not more than 10 wt % of a Group IV base oil, a Group V base oil or a combination thereof.